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Background: Observational data suggest that slowly advancing enteral feeds in preterm infants may
reduce necrotising enterocolitis but increase late-onset sepsis. The Speed of Increasing milk Feeds Trial
(SIFT) compared two rates of feed advancement.
Objective: To determine if faster (30 ml/kg/day) or slower (18 ml/kg/day) daily feed increments improve
survival without moderate or severe disability and other morbidities in very preterm or very
low-birthweight infants.
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Design: This was a multicentre, two-arm, parallel-group, randomised controlled trial. Randomisation
was via a web-hosted minimisation algorithm. It was not possible to safely and completely blind
caregivers and parents.
Setting: The setting was 55 UK neonatal units, from May 2013 to June 2015.
Participants: The participants were infants born at < 32 weeks’ gestation or a weight of < 1500 g, who
were receiving < 30 ml/kg/day of milk at trial enrolment.
Interventions: When clinicians were ready to start advancing feed volumes, the infant was randomised
to receive daily feed increments of either 30 ml/kg/day or 18 ml/kg/day. In total, 1400 infants were
allocated to fast feeds and 1404 infants were allocated to slow feeds.
Main outcome measures: The primary outcome was survival without moderate or severe
neurodevelopmental disability at 24 months of age, corrected for gestational age. The secondary
outcomes were mortality; moderate or severe neurodevelopmental disability at 24 months corrected
for gestational age; death before discharge home; microbiologically confirmed or clinically suspected
late-onset sepsis; necrotising enterocolitis (Bell’s stage 2 or 3); time taken to reach full milk feeds
(tolerating 150 ml/kg/day for 3 consecutive days); growth from birth to discharge; duration of
parenteral feeding; time in intensive care; duration of hospital stay; diagnosis of cerebral palsy by a
doctor or other health professional; and individual components of the definition of moderate or severe
neurodevelopmental disability.
Results: The results showed that survival without moderate or severe neurodevelopmental disability
at 24 months occurred in 802 out of 1224 (65.5%) infants allocated to faster increments and 848 out of
1246 (68.1%) infants allocated to slower increments (adjusted risk ratio 0.96, 95% confidence interval 0.92
to 1.01). There was no significant difference between groups in the risk of the individual components of
the primary outcome or in the important hospital outcomes: late-onset sepsis (adjusted risk ratio 0.96,
95% confidence interval 0.86 to 1.07) or necrotising enterocolitis (adjusted risk ratio 0.88, 95% confidence
interval 0.68 to 1.16). Cost–consequence analysis showed that the faster feed increment rate was less
costly but also less effective than the slower rate in terms of achieving the primary outcome, so was
therefore found to not be cost-effective. Four unexpected serious adverse events were reported, two in
each group. None was assessed as being causally related to the intervention.
Limitations: The study could not be blinded, so care may have been affected by knowledge of
allocation. Although well powered for comparisons of all infants, subgroup comparisons were
underpowered.
Conclusions: No clear advantage was identified for the important outcomes in very preterm or very
low-birthweight infants when milk feeds were advanced in daily volume increments of 30 ml/kg/day or
18 ml/kg/day. In terms of future work, the interaction of different milk types with increments merits
further examination, as may different increments in infants at the extremes of gestation or birthweight.
Trial registration: Current Controlled Trials ISRCTN76463425.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 18.
See the NIHR Journals Library website for further project information.
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Plain English summary
Some infants who are born early need to be fed through a tube into their stomach. A small volumeof milk is given to begin with, which is gradually increased. To determine whether infants do better
if they are fed faster or slower, this study compared increasing the milk feeds by 30 ml/kg/day with
increasing the milk feeds by 18 ml/kg/day, aiming to get to full feeds (when other fluids are not needed)
in 5 or 9 days. We compared results from the two groups at discharge from hospital and at 24 months
of age, after correcting for prematurity. We also assessed the economic impact of the two daily feed
increments, interviewed parents about taking part in multiple studies and tested methods for improving
questionnaire returns.
The faster-fed group reached full milk feeds sooner and needed less intravenous nutrition, and the
proportion of infants developing bowel inflammation or bloodstream infection were similar. At 24 months
of age, we found an unexpected increase in the risk of moderate or severe motor impairment in the
faster-fed group, which is difficult to explain. We also saw that other types of disability were more
frequent in the faster group, although this was not significantly different mathematically. This means
that no clear advantage of increasing feeds at faster or slower rates was identified and health professionals
will need to carefully consider how to increase feeds.
After accepting the increased risk of disability, an economic evaluation showed that increasing milk
feed volumes at a faster rate was not a cost-effective strategy. Interviews with parents showed that
they valued opportunities for their infant to take part in studies, but this interaction is complex and
difficult to remember at a stressful and confusing time and made worse by considering multiple
studies. More questionnaires were returned when vouchers were given before rather than after
receiving them.
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Scientific summary
Background
Very preterm (< 32 weeks) or very low-birthweight (< 1500 g) infants are fed increasing volumes of
milk per day, until they reach full enteral feeds. The safest approach is uncertain, with competing
concerns that advancing feed volumes quickly might increase the risk of necrotising enterocolitis but
that slower advances in feed volume might increase the risk of late-onset sepsis from longer exposure
to parenteral fluids. As these outcomes and other factors can influence neurodevelopmental outcomes,
feeding interventions (including speed of milk increments) might alter the long-term outlook of very
preterm or very low-birthweight infants.
Existing trial data are insufficient to determine whether advancing enteral feed volumes slowly (typically
< 24 ml/kg/day) or more quickly (30–40 ml/kg/day) affect these outcomes in very preterm or very low-
birthweight infants. None of the nine randomised controlled trials included in the Cochrane review prior
to the Speed of Increasing milk Feeds Trial (SIFT) published neurodevelopmental outcomes (Morgan J,
Young L, McGuire W. Slow advancement of enteral feed volumes to prevent necrotising enterocolitis
in very low-birthweight infants. Cochrane Database Syst Rev 2015;10:CD001241). The review authors
concluded ‘that advancing enteral feed volumes at daily increments of 30 to 40 ml/kg (compared to 15 to
24 ml/kg) does not increase the risk of necrotising enterocolitis or death in very low-birthweight infants’.
They also concluded that ‘advancing the volume of enteral feeds at slow rates results in several days of
delay in establishing full enteral feeds and increases the risk of invasive infection’. ‘The applicability of
these findings to extremely preterm, extremely low-birthweight, or growth-restricted infants is limited’
owing to the participants studied and ‘further randomised controlled trials in these populations may be
warranted to resolve this uncertainty’ (Morgan J, Young L, McGuire W. Slow advancement of enteral
feed volumes to prevent necrotising enterocolitis in very low-birthweight infants. Cochrane Database Syst
Rev 2015;10:CD001241). The SIFT, therefore, compared faster (30 ml/kg/day) with slower (18 ml/kg/day)
daily increments in milk feeds.
Objectives
To study the effect of two different speeds of daily milk feed increments (30 ml/kg/day vs. 18 ml/kg/day)
on survival without moderate or severe impairment at 24 months of age (corrected for gestational age),
necrotising enterocolitis, late-onset sepsis and other morbidities in very preterm or very low-birthweight
infants. We also assessed the economic impact of the two daily feed increments, interviewed parents
about taking part in multiple studies and tested methods for improving questionnaire returns.
Methods
Study design
The study was a multicentre, two-arm, parallel-group, randomised controlled trial in very preterm or
very low-birthweight infants (www.npeu.ox.ac.uk/sift; accessed 9 December 2019).
Setting
The setting was UK and Republic of Ireland neonatal units; recruitment and initial care was in 55 units
and continuing care during birth hospitalisation was in a further 78 units.
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Participants
The participants were infants born at < 32 weeks’ gestation or who had a birthweight of < 1500 g,
who were receiving < 30 ml/kg/day of milk. Infants with a known severe congenital anomaly, with no
realistic chance of survival or who were unlikely to be traceable for follow-up, were ineligible. Written,
parental consent was obtained from parents after a verbal and written explanation.
Interventions
When clinicians were ready to start advancing feed volumes, the infant was allocated randomly via
secure web-based randomisation to receive daily increments in feed volume of 30 ml/kg or 18 ml/kg.
A minimisation algorithm was used to balance prognostic factors. Multiple births were given the same
allocation. All other aspects of feeding and care followed routine clinical practice in the individual units.
Outcomes
Primary outcome
The primary outcome was survival without moderate or severe neurodevelopmental disability at
24 months of age corrected for gestational age.
Secondary outcomes
The secondary outcomes were:
l mortality
l moderate or severe neurodevelopmental disability at 24 months corrected for gestational age
l microbiologically confirmed or clinically suspected late-onset invasive sepsis
l necrotising enterocolitis (Bell’s stage 2 or 3)
l time taken to reach full milk feeds (150 ml/kg/day for 3 consecutive days)
l growth
l duration of parenteral feeding
l time in intensive care
l duration of hospital stay
l diagnosis of cerebral palsy by a doctor or other health professional
l individual components of the definition of moderate or severe neurodevelopmental disability.
Diagnoses of moderate or severe neurodevelopmental disability, late-onset sepsis and necrotising
enterocolitis were confirmed by the blinded end-point review committee using standard definitions.
All data collection forms were assessed independently by pairs of clinicians unaware of infant allocation.
Statistics and analysis plan
Sample size
It was estimated that 80% of infants would survive to 24 months of age and 11% of survivors would
have moderate or severe neurodevelopmental disability. Estimating that the primary outcome would
be seen in 71% of the comparator (slower) group, a total sample size of 2500 infants, allowing for a
questionnaire response rate of 80%, would give 90% power to detect an absolute difference of 6.3%
with a two-sided 5% significance level.
Subsequently, an inflation factor of 1.12 was applied to the sample size to allow for multiple births,
as they received the same allocation and would probably have correlated outcomes. This adjustment
assumed the proportion of multiple births to be 25% and an intraclass correlation coefficient of 0.9 for
the primary outcome at 24 months corrected for gestational age. The total target sample size was
therefore increased to 2800 infants.
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Statistical analyses
Demographic factors, clinical characteristics and outcomes were summarised with counts and percentages
for categorical variables, means and standard deviations for normally distributed continuous variables
and medians (interquartile or simple ranges) for other continuous variables. Outcomes were analysed
according to allocation, using the slower feed increment group as the comparator.
Risk ratios and 95% confidence intervals were calculated for the primary outcome at 24 months
corrected for gestational age and for the discharge outcomes of late-onset sepsis and necrotising
enterocolitis, with 99% confidence intervals used for all other dichotomous outcomes. For normally
distributed continuous outcomes, the mean difference (99% confidence interval) was presented and for
skewed continuous variables the median difference (99% confidence interval) was presented. Adjusted
risk ratios were estimated using log-binomial regression or log-Poisson regression, with a robust variance
estimator if the binomial model failed to converge. Linear regression was used for normally distributed
continuous variables and quantile regression was used for skewed continuous variables. The primary
inference was based on the analysis adjusting for the minimisation factors at randomisation. Centre was
fitted as a random effect and all other factors were fitted as fixed effects. The correlation in outcomes
between multiples and siblings born in a subsequent pregnancy during the trial period was accounted for.
The consistency of the effects of advancing milk feeds on the incidence of the primary outcome,
late-onset sepsis and necrotising enterocolitis across specific subgroups of infants was assessed using
the statistical test of interaction. Prespecified subgroup analyses included (1) week of gestation at
birth, (2) birthweight < 10th centile versus ≥ 10th centile for gestational age and (3) type of milk
received during the hospital stay. A non-prespecified analysis assessed the effect of the increments on
sepsis and necrotising enterocolitis in infants with the presence of absent or reversed umbilical arterial
blood flow on any antenatal umbilical Doppler study.
Results
From June 2013 to June 2015, 55 hospitals recruited 2804 infants; 1400 infants were allocated to
faster daily feed increments (30 ml/kg/day) and 1404 infants were allocated to slower feed increments
(18 ml/kg/day). A total of 69 infants discontinued the intervention owing to clinician or parental
preference; for 11 of these infants, parental consent was withdrawn and their data were not available
for analysis and the remainder were included in the intention-to-treat analysis. Outcome data for
discharge home were not available for eight infants; their data were included in analyses except when
knowledge of discharge or the date of discharge was required. A total of 68 (4.9%) infants in the faster
increment group and 77 (5.5%) in the slower increment group died before 24 months corrected for
gestational age. Outcome data were available for 1175 (84.3%) of the surviving infants in the faster
increment group and 1189 (85.0%) in the slower increment group at 24 months corrected for
gestational age. Baseline characteristics were well balanced, with the median gestational age at birth
being 29 weeks in both groups. Median birthweights were 1144 g in the faster increment group and
1142 g in the slower increment group. Overall, 60% of infants were born via caesarean section, 24%
infants were born following rupture of maternal amniotic membranes for > 24 hours and 16% of
infants had evidence of absent or reversed end diastolic flow in the umbilical arteries.
Primary outcome
The primary outcome (mortality or disability) was known for 1224 (87.2%) infants in the faster
increment group and 1246 (89.0%) infants in the slower increment group. In the faster increment
group, 802 out of 1224 (65.5%) infants survived to 24 months corrected for gestational age without
moderate or severe disability, compared with 848 out of 1246 (68.1%) infants in the slower increment
group: adjusted risk ratio 0.96 (95% confidence interval 0.92 to 1.01). There were no significant
differences at 24 months corrected for gestational age in either component of the combined outcome
(i.e. survival or moderate or severe disability).
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Secondary outcomes at 24 months of age corrected for gestational age
At 24 months corrected for gestational age, there was a significant difference between groups after
adjustment for the factors used in the minimisation algorithm; moderate or severe motor impairment
occurred in 87 out of 1164 (7.5%) infants in the faster increment group and 59 out of 1177 (5.0%)
infants in the slower increment group (adjusted risk ratio 1.48, 99% confidence interval 1.02 to 2.14;
p = 0.007).
There was, however, no evidence of a significant difference between groups on the other three
components of the disability definition (moderate or severe visual, hearing or cognitive impairment).
Numerically, more adverse outcomes were seen in the faster increment group for each of these
components and for the diagnosis of cerebral palsy by a doctor or other health professional, which
occurred in 5.4% of the faster increment group and 3.2% of the slower increment group (adjusted risk
ratio 1.66, 99% confidence interval 0.97 to 2.84; p = 0.015).
Other secondary outcomes
In total, 414 of 1389 (29.8%) infants in the faster increment group had microbiologically confirmed
or clinically suspected late-onset sepsis compared with 434 of 1397 (31.1%) infants in the slower
increment group (adjusted risk ratio 0.96, 95% confidence interval 0.86 to 1.07; p = 0.43). Bell’s stage 2
or 3 necrotising enterocolitis occurred in 70 out of 1394 (5.0%) infants in the faster increment group
and 78 out of 1399 (5.6%) infants in the slower increment group (adjusted risk ratio 0.88, 95%
confidence interval 0.68 to 1.16; p = 0.37).
The faster increment group reached full milk feeds significantly sooner, with an adjusted median
difference of –2.7 days (99% confidence interval –3.1 to –2.4 days; p < 0.001). Significantly fewer days
of parenteral nutrition from trial entry were received in the faster increment group (adjusted median
difference –2.2 days, 99% confidence interval –2.7 to –1.6 days; p < 0.001).
There was no evidence of between-group differences for other outcomes during hospitalisation.
Subgroup analyses
Subgroup analyses showed a significant interaction (p = 0.045) with the primary outcome for the type
of enteral milk received (human, formula or both). No significant interaction was seen with the primary
outcome for completed weeks of gestation at birth or birthweight < 10th centile or ≥ 10th centile for
gestational age (p = 0.076 and p = 0.18, respectively).
Subgroup analyses did not show any significant interactions with necrotising enterocolitis for:
l completed weeks of gestation at birth (p = 0.63)
l birthweight < 10th centile or ≥ 10th centile for gestational age (p = 0.25)
l type of enteral milk received (human, formula or both) (p = 0.53).
Subgroup analyses did not show any significant interactions with late-onset sepsis for:
l completed weeks of gestation at birth (p = 0.07)
l birthweight < 10th centile or ≥ 10th centile for gestational age (p = 0.51)
l type of enteral milk received (human, formula or both) (p = 0.56).
Other analyses
Cost–consequence analysis showed that the faster feed increment rate was less costly than but also
less effective than the slower rate in terms of achieving the primary outcome. It was therefore found
to not be cost-effective. Interviews with parents showed that they valued opportunities for their infant
to take part in studies, but this interaction is complex and difficult to remember at a stressful and
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confusing time and made worse by considering multiple studies. More questionnaires were returned
when vouchers were given before rather than after receiving them.
Safety and adverse events
Four unexpected serious adverse events were reported, two in each group. No events were assessed
as being causally related to the intervention.
Discussion
Results from this large, pragmatic, randomised controlled trial show that advancing milk feeds at daily
increments of 30 ml/kg compared with 18 ml/kg does not affect survival without moderate or severe
disability at 24 months corrected for gestational age, or the risk of late-onset sepsis, necrotising
enterocolitis, or death during hospitalisation in very preterm or very low-birthweight infants. The
number of days to reach full milk feeds and days of parenteral nutrition were reduced with faster
increments. Although these feeding outcomes favour faster increments, there was an unexpected
increase in the risk of moderate or severe motor impairment in the faster increment group that must
be considered. This observation is unexplained and there were not more cases of late-onset sepsis or
necrotising enterocolitis in the faster increment group.
These results substantially outweigh data from previous trials because large numbers of high-risk
infants were recruited, including 1020 extremely low-birthweight infants, 994 extremely preterm
infants and 435 infants with absent or reversed end diastolic flow in the umbilical artery on antenatal
Doppler studies. In the subgroup analyses, there was only evidence of excess adverse outcome in the
small number of faster increment infants who received formula milk alone. Given the small numbers
and the missing data, in the formula-only fed infants this probably represents a chance finding.
Higher-risk infants (including those with abnormal Doppler results) did not do worse with faster
increments. Infants were a median of 4 days old at commencement of the intervention and some
clinicians may have been less likely to enrol the highest-risk infants. The trial does not, therefore, allow
conclusion about the safety of different feed advancement increments in the first few days after birth.
The high follow-up rates in survivors at 24 months corrected for gestational age of 87.4% of surviving
infants in the faster increment group and 88.4% of surviving infants in the slower increment group
suggest that the results are robust and unlikely to be biased and confirm the utility of parent-report
questionnaires in combination with clinical data to obtain trial outcome measures.
Applicability
The trial was pragmatic and, apart from the daily milk volume increment, clinician preference and unit
guidelines determined other care. The SIFT, therefore, assessed the intention to increase at 18 ml/kg/day
or 30 ml/kg/day by intention-to-treat analysis and recruited a mixed population including high-risk infants.
Limitations
The trial was not blinded, as it would be difficult to safely and completely blind caregivers and parents
to the feed rate. It is possible that knowledge of allocation could alter clinician practice, for example
stopping feeds more often or diagnosing suspected necrotising enterocolitis in faster increment infants.
We did, however, see fewer cases of necrotising enterocolitis in the faster increment group, suggesting
that this did not occur often.
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Implications for research
Infants at the extremes of gestation or birthweight may react differently and further research may
be warranted in these groups. Alternative increments of milk increases may also merit further
examination, as might different increments with different milk types.
Conclusions
Advancing enteral feed volumes at daily increments of 18 ml/kg versus 30 ml/kg did not affect the
primary outcome of survival without moderate or severe neurodevelopmental disability, late-onset
sepsis or necrotising enterocolitis in very preterm or very low-birthweight infants. Advancing feeds
more quickly reduced the duration of parenteral nutrition by 2 days but was associated with an
unexpected increase in the frequency of abnormal motor outcomes.
Trial registration
This trial is registered as ISRCTN76463425.
Funding
This project was funded by the National Institute for Health Research Health Technology Assessment
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 18. See the NIHR
Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been reproduced and adapted from Abbott et al.
1 This article is
distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license and indicate if changes were made. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.
Outcomes affected by feeding strategies
In the UK, 1–2% of newborn infants are very preterm or have a very low birthweight (VLBW). Preterm
birth is the major risk factor for infant mortality, with 73% of neonatal deaths in the UK occurring in
infants born before 37 completed weeks of gestation.2 As survival, especially of very preterm infants,
has increased in recent years,3 the high prevalence of morbidity associated with preterm birth means
that the assessment of long-term outcomes has become increasingly important.4 Short- and long-term
outcomes for preterm infants are affected by strategies that reduce infection rates, lower necrotising
enterocolitis (NEC) rates, promote adequate growth and maintain access to tertiary-level facilities.
Optimising infant feeding strategies offers the potential to improve all of these outcomes. Benefits are
likely to arise from both the individual and the combined effects of identifying the optimum feeding
strategy, as the rates of such complications in very preterm infants are high. NEC that is severe enough
to cause death or require surgery affects approximately 7.5% of infants born before 29 weeks of
gestation and is the cause of death in 11% of the deaths of infants born before 32 weeks’ gestation.5
Late-onset sepsis (LOS) affects around 25% of very preterm infants and is responsible for 10% of deaths
in the same population. Long-term data following LOS or NEC suggest that these conditions almost
double the risk of poor neurodevelopmental outcome.6 Preterm infants are at significant risk of poor
long-term neurodevelopmental problems: almost 12% of infants have moderate or severe disability,7
with both sepsis and NEC dramatically increasing this risk.8–13
Nutritional support of preterm infants and speed of increasing milk feeds
Every year in the UK, around 8000 infants are born so preterm that they cannot initially be fed milk
and, therefore, require intravenous nutrition. Milk feeding is gradually increased as the immature gut
begins to tolerate milk and intravenous nutrition is correspondingly reduced, but there are few data
determining how quickly this is best achieved.14 One of the most serious complications of intravenous
feeding is LOS, which occurs in 27% of infants born weighing < 1500 g at birth or under 29 weeks’
gestation.14 LOS is known to cause poor long-term cognitive outcomes, liver damage and sudden death
from cardiac problems resulting from misplaced catheters.15–17 One of the most common late-onset
infections is ‘catheter-related bloodstream infection’; the risk of bloodstream infection is directly
related to the time the catheter is indwelling in the bloodstream.18–20 The more rapid advancement of
enteral feeds described in this study will, in principle, reduce exposure to intravenous nutrition by
causing infants to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days) approximately
4 days earlier than the slower advancement. Reducing exposure by this amount could reduce the
number of infections by between 5 and 15 cases per 250 infants, which is an absolute risk reduction of
4%. This is possibly an underestimate of the reduction, as infection risk increases with the length of
time a catheter is in place.21,22
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However, faster increases in milk feed volumes may increase the likelihood of NEC that, as well as
being potentially fatal, may provoke intolerance of feeds or gut dysfunction, which could result in
longer times to achieve full feeds rather than shorter. Survivors of NEC also have significantly worse
long-term outcomes across multiple developmental domains than those who are unaffected.6,23
Therefore, although emerging data suggest that better health outcomes may be achieved with faster
feeding increments, there are possible disadvantages of this and a randomised controlled trial (RCT) is
required to support a change in clinical practice.14
Existing evidence
Existing trial data are insufficient to determine whether or not advancing enteral feed volumes slowly
(typically < 24 ml/kg/day) or more quickly (daily increments of 30–40 ml/kg) affects outcomes, including
the risk of neurological impairment, LOS or NEC in very preterm or VLBW infants.14,24–32 The Cochrane
review14 included nine RCTs with a total of 949 participants (Box 1). None of the studies prior to The
Speed of Increasing milk Feeds Trial (SIFT) published neurodevelopmental outcomes in early childhood
and the Cochrane review authors concluded ‘that advancing enteral feed volumes at daily increments
of 30 to 40 ml/kg (compared to 15 to 24 ml/kg) does not increase the risk of NEC or death in VLBW
infants’.14 They also concluded that ‘advancing the volume of enteral feeds at slow rates results in several
days of delay in establishing full enteral feeds and increases the risk of invasive infection’.14 ‘The
applicability of these findings to extremely preterm, extremely low-birthweight or growth-restricted
infants is limited’ due to the participants studied and ‘further randomised controlled trials in these
populations may be warranted to resolve this uncertainty’.14 SIFT provided this information by recruiting
a large number of infants, including those at highest risk.
Objective
The study aimed to assess if faster (30 ml/kg/day) or slower (18 ml/kg/day) daily feed increments
improve survival without moderate or severe disability at 24 months of age [corrected for gestational
age (CGA)] and other morbidity and mortality in very preterm and/or VLBW infants.
BOX 1 Summary findings of the Cochrane review meta-analyses14
Late-onset infection (invasive infection)
l Typical RR 1.46, 95% CI 1.03 to 2.06; typical RD 0.07, 95% CI 0.01 to 0.13; number needed to harm 14,
95% CI 8 to 100; six trials, 553 participants.
Necrotising enterocolitis (Bell’s stage 2/3)
l Typical RR 1.02, 95% CI 0.64 to 1.62; typical RD –0.00, 95% CI –0.03 to 0.03; nine trials,
949 participants.
All-cause mortality
l Typical RR 1.18, 95% CI 0.90 to 1.53; typical RD 0.03, 95% CI –0.02 to 0.08; eight trials,
791 participants.
CI, confidence interval; RD, risk difference; RR, risk ratio.
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Chapter 2 Methods
Parts of this chapter have been reproduced and adapted from Abbott et al.
1 This article is
distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license and indicate if changes were made. The Creative
Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies
to the data made available in this article, unless otherwise stated.
Design
The SIFT was a multicentre, two-arm, non-blinded, parallel-group RCT in very preterm and/or VLBW
infants in the UK and the Republic of Ireland.1,33
Ethics approval and research governance
The SIFT protocol33 was approved by the National Research Ethics Service (NRES) Committee East
Midlands – Nottingham 2 on 31 January 2013 (reference 13/EM/0030). Local approval and site-specific
assessments were obtained from the NHS trusts for trial sites. The trial was registered with the
International Standard Randomised Controlled Trial Register (https://doi.org/10.1186/ISRCTN76463425).
Patient and public involvement
The planning and delivery of the SIFT was facilitated by close engagement with infant and family
representatives who were experienced in service-user representation. Bliss (www.bliss.org.uk/; accessed
29 August 2019), the UK national charity for ‘babies born premature or sick’, was the most heavily
involved charity. Parents of children who had received neonatal intensive care contributed directly and
via Bliss to both the development of trial materials [e.g. parent information leaflets (PILs) and consent
forms] and training research staff (e.g. in simulated ‘consent-seeking’ sessions). INVOLVE good practice
guidelines were followed to ensure service-user leadership in the trial delivery and dissemination of the
findings. INVOLVE is a national advisory group established and funded by the National Institute for
Health Research (NIHR) to support active public involvement in NHS, public health and social care
research (www.invo.org.uk/about-involve/; accessed 9 December 2019).
Participants
Inclusion criteria
l Gestational age at birth of < 32 weeks and/or birthweight of < 1500 g.
l Receiving ≤ 30 ml/kg/day of milk at randomisation.
l Written informed parental consent.
Exclusion criteria
l Severe congenital anomaly.
l No realistic prospect of survival.
l Unlikely to be traceable for follow-up at 24 months of age (e.g. infants of non-UK residents).
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Setting
The setting was neonatal units caring for very preterm infants in the UK and the Republic of Ireland:
l Recruiting sites – parental consent was obtained, infants were enrolled by randomisation and
participation in the trial was commenced (n = 55; see Appendix 1).
l Continuing care sites – clinicians continued to administer the intervention and collect data if a
participant was transferred from a recruiting or another continuing care site (n = 78; see
Appendix 2).
Infants were able to participate in other clinical trials at the same time as taking part in the SIFT,
depending on the nature of the interventions in the other trials. The Enteral Lactoferrin In Neonates
(ELFIN) trial was designed alongside the SIFT to allow enrolment of infants into both trials.1,34 The SIFT
and the ELFIN trial shared some procedures including some joint data collection forms and other
documents. Other trials running concurrently were discussed by the chief investigators or their
delegated representative, who agreed whether or not joint recruitment was appropriate.
Screening and eligibility assessment
The local health-care team identified potential participants who met the eligibility criteria. Exclusion
criteria were defined and assessed by clinicians. Assessment of eligibility was accepted to be within the
scope of competency of appropriately trained and experienced neonatal nurses, as no specific medical
assessments were required. Competency was formally delegated by the principal investigator (PI) on
the delegation log.
Informed consent and recruitment
Parents of potential participants were approached only after receiving a PIL, which gave a full verbal
and written explanation of the trial. Parents who did not speak English were approached only if an
adult interpreter was available and if they were likely to be resident in the UK or the Republic of
Ireland for at least 2 years.
The consent-seeking process included informing parents of the possible benefits and risks as a staged
process.35 If the anticipated infant was likely to be eligible to participate in the trial, preliminary verbal
information and the PIL were offered prior to birth and this was followed up after birth. For infants
who were not identified antenatally or if other issues took precedence, information was provided
after birth.
Written informed parental consent was obtained by means of a dated parental signature and the
signature of the person who obtained the informed consent; this was the PI or the health-care
professional with delegated authority. The parents were given a copy of the signed informed consent
form. A copy was retained both in the infant’s medical notes and in the site file by the PI and the
original copy was posted to the trials unit co-ordinating centre.
No financial or material incentive or compensation was given to the participants or parents to take
part. It was highlighted to parents that they were free to withdraw their infant from the trial at any
time without the need to provide an explanation or reason. The PIL explained that such a decision
would not affect any aspect of clinical care.
METHODS
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The trial entry form was completed after informed consent was received. Information on the form was
then entered in the randomisation website hosted by the National Perinatal Epidemiology Unit (NPEU)
Clinical Trial Unit (CTU) (https://rct.npeu.ox.ac.uk/; accessed 30 May 2015). Randomisation took place
when the clinicians were ready to increase the feeds to > 30 ml/kg/day. Infants were considered
to have been enrolled once they were allocated a study number and one of the two rates of
feeding increment.
Interventions
Trial participants were allocated randomly to receive daily increments in milk feed volume of either
30 ml/kg or 18 ml/kg.
All other aspects of feeding and care followed routine clinical practice in the individual units, including
the capacity to stop or alter the rate of the increase in feeds if clinically indicated.
Randomisation
Randomisation was performed by computer through a secure website hosted by the NPEU CTU,
University of Oxford. A minimisation algorithm was used to balance prognostic factors: hospital,
multiple birth, gestational age ranges and birthweight of < 10th centile for gestational age. The
algorithm included a random component that minimises with 80% probability of reducing predictability.
Multiple births were allocated to the same feeding increment rate.
Allocation concealment and blinding
The allocation sequence was concealed from those who were assigning participants by the web-based
randomisation. It was not possible to safely and completely blind caregivers and parents to the feed
rate. This was because nurses, doctors and parents indicated the need to know how much milk was
being given as part of feeding practice and care-giving. Blinded end-point reviewers were not aware of
the allocation for any participant when reviewing the outcome data.
Primary and secondary outcomes
The primary outcome was survival without moderate or severe neurodevelopmental disability at
24 months of age CGA. Moderate or severe neurodevelopmental disability was defined as any of:
l moderate or severe visual impairment (i.e. reduced vision uncorrected with aids, blind in one eye
with good vision in the contralateral eye or blind/perceives light only)
l moderate or severe hearing impairment (i.e. hearing loss corrected with hearing aids, some hearing
loss but not corrected by hearing aids, or deaf)
l moderate or severe gross motor impairment (i.e. unable to walk or sit independently)
l moderate or severe cognitive impairment, assessed using the Parent Report of Children’s
Abilities – Revised (PARCA-R).
A total PARCA-R score of < 44 was used to identify children with moderate or severe cognitive
impairment.38 The definition is summarised in Box 2.
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Secondary outcomes included:
l mortality
l moderate or severe neurodevelopmental disability at 24 months CGA
l death before discharge home
l microbiologically confirmed (Box 3) or clinically suspected late-onset invasive sepsis (Box 4) from
trial entry to discharge home
l NEC (Bell’s stage 2 or 3) from trial entry to discharge home40–42
l time taken to reach full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
l growth (change in weight and head circumference z-score for gestational age) from birth to
discharge home
l duration of parenteral feeding
l duration of time in intensive care
l duration of hospital stay to discharge home
l diagnosis of cerebral palsy by a doctor or other health professional
l the individual components of the definition of moderate or severe neurodevelopmental disability.
BOX 2 Definition of moderate or severe disability
For live infants, a parent-report questionnaire was used to assess sensory and gross motor impairment and
standardised measures were used to assess cognitive function in order to identify children with:
l Moderate/severe visual impairment (reduced vision uncorrected with aids, blind in one eye with good
vision in the contralateral eye or blind/perceives light only).
l Moderate/severe hearing impairment (hearing loss corrected with aids, some hearing loss but not
corrected by aids, or deaf).
l Moderate/severe gross motor impairment (unable to walk or sit independently).
l Moderate/severe cognitive impairment assessed using the PARCA-R. Total PARCA-R scores of < 44
were used to identify children with moderate/severe cognitive impairment.36,37
A child who has any one or more of these impairments will be classified as having a moderate/severe
disability.
Definitions for motor and sensory impairments described above are as defined in the report published by,
and reproduced with permission from, the British Association of Perinatal Medicine in 2008.38
BOX 3 Definition of microbiologically confirmed late-onset infection
Microbiological culture of potentially pathogenic bacteria (including coagulase-negative staphylococci species,
but excluding probable skin contaminants such as diphtheroids, micrococci, propionibacteria, or a mixed flora)
or fungi from blood or cerebrospinal fluid sampled aseptically more than 72 h after birth, and treatment, or
clinician intention to treat, for 5 days or more with intravenous antibiotics (excluding antimicrobial prophylaxis)
after investigation was done. If the infant died or was discharged or transferred before the completion of 5 days
of antibiotics, this condition would still be met if the intention was to treat for at least 5 days.
Reproduced from The ELFIN Trial Investigators Group.39 (© The authors. Published by Elsevier Ltd. This is
an Open Access article under the CC BY-NC-ND 4.0 license. See https://creativecommons.org/licenses/
by-nc-nd/4.0/.)
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Diagnoses of moderate or severe neurodevelopmental disability, LOS and NEC were confirmed by the
blinded end-point review committee (BERC) using standard definitions (see Appendix 3 and the published
protocol1,33). All of the data collection forms were assessed independently by pairs of clinicians who were
unaware of allocation.We noted that owing to ‘rounding’ of the feed rate to the nearest 0.5 ml or to small
changes in a daily weight in the clinical setting, some infants on ‘full feeds’ received only 146–149ml/kg/day.
We therefore considered an infant to be on full feeds if ≥ 145ml/kg/day was tolerated for 3 consecutive
days. Infants who did not meet these criteria were reviewed by the BERC to determine if a sustained
level of feeding at a level below this had been achieved before discharge. Examples of this included feeds
being stopped during transfer or for a procedure, use of higher-calorie formula or fluid restriction after
150ml/kg/day had been reached.
Sample size
It was estimated that 80% of infants would survive to 24 months of age and 11% of survivors would
have moderate or severe neurodevelopmental disability.7 It was expected that the proportion with the
primary outcome would be 71% in the comparator (slower increment) group. With a total sample size
of 2500 and allowing for a questionnaire response rate of 80%, there would be 90% power to detect
an absolute difference of 6.3% with a two-sided 5% significance level. Similarly, a sample size of 2500
infants would have 90% power to detect an absolute difference of 5.4% (from 25.0% in the comparator
group) in the incidence of LOS43 and an absolute difference of 3.5% (from 6.0% in comparator group) in
the incidence of NEC (Bell’s stage 2 or 3).40–42
Subsequently, an inflation factor of 1.12 was applied to the sample size to allow for multiple births as
they received the same allocation and would probably have correlated outcomes. This adjustment
BOX 4 Definition of clinically suspected late-onset infection
Absence of positive microbiological culture, or culture of a mixed microbial flora or of probable skin
contaminants (ie,diphtheroids, micrococci, propionibacteria) only, and treatment or clinician intention to treat
for 5 days or more with intravenous antibiotics (excluding antimicrobial prophylaxis) after the investigation was
undertaken for an infant who presents at least 3 of the following clinical or laboratory features of invasive
infection:
l increase in oxygen requirement or ventilatory support
l increase in frequency of episodes of bradycardia or apnoea
l temperature instability
l ileus or enteral feeds intolerance or abdominal distension
l reduced urine output to less than 1 mL/kg per h
l impaired peripheral perfusion (capillary refill time longer than 3 seconds, skin mottling or core-
peripheral temperature gap greater than 2°C)
l hypotension (clinician-defined as needing volume or inotrope support)
l irritability, lethargy, or hypotonia (clinician-defined))
l increase in serum C-reactive protein concentrations to more than 15 mg/L or in procalcitonin
concentrations to 2 ng/mL or more
l white blood cells count smaller than 4×109/L or greater than 20×109/L
l platelet count less than 100×109/L
l glucose intolerance (blood glucose smaller than 40 mg/dL or greater than 180 mg/dL)
l metabolic acidosis (base excess less than –10 mmol/L or lactate concentration greater than 2 mmol/L).
Reproduced from The ELFIN Trial Investigators Group.39 (© The authors. Published by Elsevier Ltd. This is
an Open Access article under the CC BY-NC-ND 4.0 license. See https://creativecommons.org/licenses/
by-nc-nd/4.0/.)
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assumed the proportion of multiple births to be 25% and an intraclass correlation coefficient of 0.9 for
the primary outcome at 24 months CGA, based on a previous study.44 The total target sample size was
therefore increased to 2800.
Statistical analyses
Demographic factors, baseline clinical characteristics and outcomes were summarised with counts and
percentages for categorical variables, means [standard deviations (SDs)] for normally distributed
continuous variables and medians [interquartile ranges (IQRs) or simple ranges] for other continuous
variables. Outcomes were analysed according to allocation, using the slower fed group as the comparator.
Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated for the primary outcome at
24 months CGA and for the discharge outcomes of LOS and NEC, with a 99% CI used for all other
dichotomous outcomes to allow for multiple comparisons. For normally distributed continuous
outcomes, the mean difference (99% CI) was presented; for skewed continuous variables, the median
difference (99% CI) was presented. Adjusted risk ratios were estimated using log-binomial regression,
or log-Poisson regression with a robust variance estimator if the binomial model failed to converge.
Linear regression was used for normally distributed continuous variables and quantile regression was
used for skewed continuous variables. The primary inference was based on the analysis adjusting for
the minimisation factors at randomisation. Centre was fitted as a random effect and all other factors
were fitted as fixed effects. The mother’s identification was nested within centre to take account of the
additional level of clustering due to multiples and siblings. This adjusts the standard error to allow for
the lack of independence in trial allocation and the potential correlation in outcome.
The consistency of the effects of advancing milk feeds on the incidence of the primary outcome, LOS
and NEC across specific subgroups of infants was assessed using the statistical test of interaction.
Prespecified subgroup analyses included (1) week of gestation at birth, (2) birthweight of < 10th centile
versus ≥ 10th centile for gestational age and (3) type of milk received during the hospital stay (i.e.
breast milk only/formula only/mixed) (see Figures 3 and 4). A non-prespecified analysis assessed the
effect of the speed increments on sepsis and NEC in infants with abnormal Doppler ultrasounds (see
Table 4). Other deviations from the protocol included the use of quantile regression instead of Cox
regression to analyse time to full feeds (as the Cox proportional hazard assumption was not satisfied)
and mixed-effect log-binomial-Poisson models instead of generalised estimating equations (owing to
the ease and flexibility of these methods, which were not in common use when the study was
conceived). We performed a sensitivity analysis to examine the affect of missing data at 24 months on
the primary outcome by considering different scenarios departing from the assumption that data were
missing completely at random.
Data collection
All outcome data for this trial were routinely recorded clinical items that could be obtained from the
clinical notes or local microbiology laboratory records. Information was collected using the data
collection forms (see Appendix 5).
A BERC, masked to participant allocation, reviewed all case report forms (CRFs) that reported moderate
or severe impairment at 24 months of age CGA, episodes of LOS, episodes of NEC or episodes of other
gastrointestinal pathology. Two members who were blind to allocation independently assessed adherence
to case definitions and resolved any disagreements or discrepancies by discussion or referral to a third
committee member, or both. Persisting uncertainties were discussed with the site PI or research nurse or
both until resolved.
METHODS
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We noted that owing to ‘rounding’ of the feed rate to the nearest 0.5 ml or to small changes in a
daily weight in the clinical setting, some infants on ‘full feeds’ received only 146–149 ml/kg/day. We
therefore considered an infant to be on full feeds if ≥ 145 ml/kg/day was tolerated for 3 consecutive
days. Infants who did not meet this criterion were reviewed by the BERC to determine if a sustained
level of feeding at a level below this had been achieved before discharge. Examples of this included
feeds being stopped during transfer or for a procedure, use of higher-calorie formula or fluid
restriction after 150 ml/kg/day had been reached.
Adverse event reporting
Adverse events were defined as serious if they:
l resulted in death
l were life-threatening
l required inpatient hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability/incapacity
l were a congenital anomaly/birth defect.
The term ‘life-threatening’ refers to an event in which the participant was at risk of death at the time
of the event; it does not refer to an event that hypothetically might have caused death if it were more
severe. Serious adverse events (SAEs) were to be reported from randomisation to discharge home.
Expected SAEs were those that could be reasonably expected to occur in the population of eligible
infants during the course of the trial or form part of the outcome data. These did not require reporting
by the SIFT co-ordinating centre and referred to the following SAEs:
l death (unless unexpected in this population)
l NEC or focal intestinal perforation
l microbiologically confirmed or clinically suspected late-onset invasive infection
l bronchopulmonary dysplasia (mechanical ventilator support or supplemental oxygen at 36 weeks’
postmenstrual age)
l intracranial abnormality (i.e. haemorrhage, parenchymal infarction or white matter damage) on
cranial ultrasound scan or other imaging
l pulmonary haemorrhage
l patent ductus arteriosus requiring treatment (non-steroidal anti-inflammatory drugs or surgery)
l retinopathy of prematurity.
Reporting procedures
All expected SAEs (detailed above) were recorded on a CRF and were reviewed by the Data Monitoring
Committee (DMC) at regular intervals throughout the trial. Any unexpected SAEs (a SAE that was not
included in the list of expected SAEs) were reported by trial sites to the SIFT co-ordinating centre as
soon as possible after the event had been recognised. Information on each SAE was recorded on a SAE
reporting form, which was faxed to the SIFT co-ordinating centre. Additional information received for a
case (follow-up or corrections to the original case) were faxed to the SIFT co-ordinating centre on a new
SAE CRF. A standard operating procedure (SOP) that outlined the reporting procedure for clinicians was
provided with the SAE form and in the trial handbook. The SIFT co-ordinating centre processed and
reported the events, as specified in the CTU SOPs. The chief investigator informed all of the investigators
concerned of the relevant information about unexpected SAEs that could adversely affect the safety of
participants. Once per year throughout the recruiting period of the trial, a safety report was submitted to
the sponsor and ethics committee.
DOI: 10.3310/hta24180 Health Technology Assessment 2020 Vol. 24 No. 18
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Dorling et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
9
Economic analysis
A health economic analysis of the two speeds of milk feed increments was performed in this study and
is described in Chapter 4.
Governance and monitoring
Structured training for site investigators, local research nurses and other clinical staff was provided
during initiation meetings. Training covered areas such as seeking consent, protocol details and
processes and governance requirements. These events were supported with bespoke written and
online training materials that were available to all staff via the trial website (www.npeu.ox.ac.uk/sift/
neonatal-staff; accessed 9 January 2020). Staff in continuing care sites were directed to online training
and advised to access support from the trial team as needed.
Ongoing monitoring included review of the investigator site files that contained delegation logs,
good clinical practice certificates and research curricula vitae of staff. Best-practice data management
procedures and data monitoring at the study data centre and trial centres were followed to achieve
quality assurance. Data management was in accordance with SOPs at the trial co-ordinating centre
(NPEU CTU) and a prespecified plan. Data monitoring included review of consent forms and participant
eligibility. Additional validation checks of data were carried out regularly, with data queries issued to
study sites for resolution. Final data validation checks were carried out before database lock, with
questions being resolved by discussion with the site PI or local research nurse where possible.
During the trial, the study statisticians produced reports for the independent Trial Steering Committee
(TSC) and the independent DMC. Data quality concerns that were identified by study statisticians were
reported to study data management staff and were queried when appropriate or included in future
routine data validation checks, or both. Opportunities for external, independent review of summary
data were provided by the DMC and the TSC meetings.
Summary of changes to the study protocol
A summary of the changes made to the original protocol is presented in Appendix 7.
METHODS
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Chapter 3 Results
Recruitment and retention
Patient flow, including recruitment to and retention in the trial, is detailed in Figure 1. The trial recruited
infants from June 2013 to June 2015 in 55 hospitals. In total, the trial recruited 2804 infants; 1400
infants were allocated to faster daily feed increments (30 ml/kg/day) and 1404 were allocated to
receive slower feed increments (18 ml/kg/day). The trial was closed on reaching the sample size. All
infants received the allocated intervention, but 69 infants discontinued the intervention as a result of
clinician or parental preference (see Figure 1). For 11 of these infants, parental consent was withdrawn
and their data were not available for analysis, but the remainder were included in the intention-to-treat
analysis. Outcome data at discharge home were not available for eight infants; their data were included
in analyses except when knowledge of discharge or the date of discharge was required. In total, 68
(4.9%) infants in the faster increment group and 77 (5.5%) in the slower increment group died before
24 months CGA. Outcome data on disability at 24 months CGA were available for 1156 (87.2%)
surviving infants in the faster increment group and 1169 (88.4%) in the slower increment group. The
primary outcome (mortality or disability) was therefore known for 1224 (87.8%) infants in the faster
increment group and 1246 (89.0%) in the slower increment group (see Figure 1 and Appendix 8).
Infants included in analysis of
outcomes at discharge
(n = 1394)
Withdrew consent
to use data
(n = 6)
Infants allocated faster daily
feed increments (30  ml/kg/day)
(n = 1400)
Infants randomised
(n = 2804)
Withdrew consent
to use data
(n = 5)
Infants included in analysis of
outcomes at discharge
(n = 1399)
• Died before 24 months
    CGA, n = 68
• Missing primary outcome
    data, n = 170
• Died before 24 months
    CGA, n = 77
• Missing primary outcome
    data, n = 153
Infants included in analysis of primary
outcome at 24 months CGA (including
68 infants who died)
(n = 1224)
Infants included in analysis of primary
outcome at 24 months CGA (including
77 infants who died)
 (n = 1246)
Infants allocated to slower daily
feed increments (18  ml/kg/day)
(n = 1404)
• Randomised in error, n = 5
• Discontinued intervention, n = 40
• Withdrawn, n = 37
• Transferred to non-participating site, n = 3
• Randomised in error, n = 0
• Discontinued intervention, n = 29
• Withdrawn, n = 29
• Women, n = 2440
FIGURE 1 Flow of participants through the trial. Adapted from New England Journal of Medicine, Dorling et al.45
Controlled trial of two incremental milk-feeding rates in preterm infants. N Engl J Med 2019;381:1434–43.
Copyright © 2019 Massachusetts Medical Society.
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Demographic and other baseline characteristics
The baseline characteristics and demographic features of the participating infants were well balanced
between the two feeding increment groups (Table 1). The median gestational age was 29 weeks in
both groups (36% at < 28 weeks). The mean birthweight was 1144 g in the faster increment group
and 1142 g in the slower increment group. Overall, 60% of infants were born via caesarean section;
TABLE 1 Infant and maternal characteristics at randomisation
Characteristic
Faster feed increment group
(30ml/kg/day) (N= 1394)
Slower feed increment group
(18ml/kg/day) (N= 1399)
Number of centres,a n 55 54
Male sex, n/N (%) 739/1394 (53.0) 726/1398 (51.9)
Missing, n 0 1
Infant age at randomisation (days)
Median (IQR) 4 (3–6) 4 (3–6)
Birthweight of < 10th centile for gestational agea
Total, n/N (%) 295/1394 (21.2) 291/1398 (20.8)
Missing, n 0 1
Gestation at delivery (completed weeks),a n/N (%)
Median (IQR) 29 (27–30) 29 (27–30)
23+0 to 23+6 30/1394 (2.2) 31/1399 (2.2)
24+0 to 24+6 72/1394 (5.2) 69/1399 (4.9)
25+0 to 25+6 103/1394 (7.4) 101/1399 (7.2)
26+0 to 27+6 291/1394 (20.9) 297/1399 (21.2)
28+0 to 29+6 377/1394 (27.0) 383/1399 (27.4)
30+0 to 31+6 432/1394 (31.0) 432/1399 (30.9)
32+0 to 36+6 88/1394 (6.3) 86/1399 (6.1)
≥ 37 +0 1/1394 (0.1) 0/1399 (0.0)
Birthweight (g), n/N (%)
Mean (SD) 1144.2 (339.3) 1142.3 (328.9)
< 500 10/1394 (0.7) 7/1399 (0.5)
500 to 749 178/1394 (12.8) 164/1399 (11.7)
750 to 999 316/1394 (22.7) 345/1399 (24.7)
1000 to 1249 348/1394 (25.0) 349/1399 (24.9)
1250 to 1499 313/1394 (22.5) 328/1399 (23.4)
≥ 1500 229/1394 (16.4) 206/1399 (14.7)
Infant heart rate > 100 beats per minute at 5 minutes
Total, n/N (%) 1263/1374 (91.9) 1265/1381 (91.6)
Missing, n 20 18
Infant temperature on admission (°C)
Mean (SD) 36.8 (0.7) 36.8 (0.8)
Missing, n 8 8
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TABLE 1 Infant and maternal characteristics at randomisation (continued )
Characteristic
Faster feed increment group
(30ml/kg/day) (N= 1394)
Slower feed increment group
(18ml/kg/day) (N= 1399)
Infant worst base excess within the first 24 hours of birth (mEq/l)
Mean (SD) –6.1 (4.0) –6.1 (3.9)
Missing, n 29 26
Infant ventilated via endotracheal tube at randomisation
Total, n/N (%) 316/1392 (22.7) 293/1397 (21.0)
Missing, n 2 2
Infant had absent or reversed end diastolic flow
Total, n/N (%) 209/1372 (15.2) 226/1380 (16.4)
Missing, n 22 19
Time from trial entry to first feed (days)
Median (IQR) 0 (0–0) 0 (0–1)
Missing, n 5 4
Mother’s age at randomisation (years)
Mean (SD) 30.5 (6.2) 30.7 (6.2)
Missing, n 0 1
Multiple pregnancy
Multiple pregnancy,a,b n/N (%) 412/1394 (29.6) 411/1399 (29.4)
Singlesc 3 5
Twinsd 358 359
Tripletse 51 47
Caesarean section delivery
Total, n/N (%) 841/1393 (60.4) 847/1399 (60.5)
Missing, n 1 0
Membranes ruptured before labour
Total, n/N (%) 496/1373 (36.1) 486/1380 (35.2)
Missing, n 21 19
Membranes ruptured > 24 hours before delivery
Total, n/N (%) 323/1377 (23.5) 338/1380 (24.5)
Missing, n 17 19
a Minimisation factor.
b Sometimes, only one infant from a multiple pregnancy met the inclusion criteria and was recruited.
c Number of infants from multiple pregnancies where the other fetuses were aborted, miscarried or stillborn.
d Number of infants who were one of twins.
e Number of infants who were one of triplets.
Note
Unless otherwise stated, the table gives the percentages of infants with data in that group of the trial who had
(or whose mother had) the stated characteristic.
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in
preterm infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
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24% of infants were born following rupture of maternal amniotic membranes for > 24 hours; and 16%
of infants had evidence of absent or reversed end diastolic flow in the fetal umbilical arteries. The
allocation groups were well balanced in individual recruiting sites, as per the minimisation algorithm
(see Appendix 9).
Adherence
All of the infants received the allocated intervention but 69 infants discontinued the intervention:
66 from clinician or parental preference and three from transfer to a non-participating hospital (see Figure 1).
For 11 of these 66 infants, parental consent was withdrawn and their data were not available for analysis.
The remainder were included in intention-to-treat analyses. Outcome data at discharge home were not
available for eight infants; their data were included in analyses except when knowledge of discharge
or the date of discharge was required. In total, 68 (4.9%) infants in the faster increment group and
77 (5.5%) in the slower increment group died before 24 months CGA. Primary outcome classification at
24 months CGA was possible in 1224 (87.8%) infants in the faster increment group and 1246 (89.0%) in
the slower increment group.
Outcomes
The estimates of effect for the primary and secondary outcomes are presented in Table 2 for outcomes
at 24 months of age CGA and Table 3 for outcomes at hospital discharge.
TABLE 2 Primary and secondary outcomes at 24 months of age CGA
Outcome at 24 months
of age CGA
Faster feed
increment group
(30ml/kg/day)
(N= 1394)
Slower feed
increment group
(18ml/kg/day)
(N= 1399)
Unadjusted
effect
measure (CI)a,b
Adjusted effect
measure (CI)a,b,c p-valued
Primary outcome
Survival without moderate
or severe disability,e
n/N (%)
802/1224 (65.5) 848/1246 (68.1) 0.96
(0.91 to 1.02)
0.96
(0.92 to 1.01)
0.16
Missing, n 170 153
Survival, n/N (%) 1326/1394 (95.1) 1322/1399 (94.5) 1.01
(0.99 to 1.02)
1.01
(0.99 to 1.03)
0.55
Missing, n 0 0
Moderate or severe
disability, n/N (%)
354/1156 (30.6) 321/1169 (27.5) 1.12
(0.98 to 1.28)
1.10
(0.97 to 1.25)
0.12
Missing, n 238 230
Secondary outcome
Moderate or severe visual
impairment, n/N (%)
21/1156 (1.8) 16/1171 (1.4) 1.33
(0.57 to 3.10)
1.28
(0.43 to 3.83)
0.57
Missing, n 238 228
Moderate or severe
hearing impairment,
n/N (%)
58/1143 (5.1) 41/1172 (3.5) 1.45
(0.86 to 2.46)
1.43
(0.79 to 2.57)
0.12
Missing, n 251 227
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TABLE 2 Primary and secondary outcomes at 24 months of age CGA (continued )
Outcome at 24 months
of age CGA
Faster feed
increment group
(30ml/kg/day)
(N= 1394)
Slower feed
increment group
(18ml/kg/day)
(N= 1399)
Unadjusted
effect
measure (CI)a,b
Adjusted effect
measure (CI)a,b,c p-valued
Moderate or severe motor
impairment, n/N (%)
87/1164 (7.5) 59/1177 (5.0) 1.49
(0.96 to 2.32)
1.48
(1.02 to 2.14)
0.007
Missing, n 230 222
Moderate or severe
cognitive impairment,
n/N (%)
307/1156 (26.6) 289/1170 (24.7) 1.08
(0.89 to 1.30)
1.06
(0.89 to 1.27)
0.39
Missing, n 238 229
PARCA-R
Composite score
Mean (SD) 72.5 (38.3) 73.9 (37.8) –1.46
(–6.31 to 3.39)
–0.62
(–4.82 to 3.59)
0.71
Median (IQR) 69 (40–100) 70 (43–101)
Missing, n 419 392
Non-verbal cognition scale score
Mean (SD) 25.1 (6.2) 25.5 (5.7) –0.45
(–1.18 to 0.29)
–0.36
(–1.01 to 0.29)
0.15
Median (IQR) 27 (23–29) 27 (23–29)
Missing, n 414 390
Vocabulary subscale score
Mean (SD) 39.3 (29.7) 40.3 (30.1) –0.99
(–4.81 to 2.83)
–0.37
(–3.71 to 2.97)
0.78
Median (IQR) 34 (13–60) 35 (14–62)
Missing, n 412 383
Sentence complexity subscale score
Mean (SD) 7.9 (5.7) 7.9 (5.4) –0.09
(–0.79 to 0.61)
–0.05
(–0.73 to 0.64)
0.86
Median (IQR) 7 (3–12) 8 (4–11)
Missing, n 405 379
Diagnosis of cerebral palsy by a doctor or other health professional
Total, n/N (%) 58/1084 (5.4) 35/1099 (3.2) 1.68
(0.97 to 2.91)
1.66
(0.97 to 2.84)
0.015
Missing, n 310 300
a Risk ratios for binary outcomes and mean differences for continuous outcomes.
b 95% CIs for survival without moderate/severe disability, survival and moderate/severe disability at 24 months CGA
(primary outcomes). 99% CIs for all other outcomes (secondary outcomes).
c Adjusted for minimisation factors: collaborating hospital, single or multiple birth, gestational age at birth and
birthweight of < 10th centile for gestational age where technically possible.
d p-value for testing whether adjusted risk ratio is equal to 1 or adjusted mean difference is equal to 0.
e Moderate/severe disability is defined as one or more of the following: visual impairment, hearing impairment,
motor impairment or cognitive impairment (PARCA-R composite score of < 44). Definitions of motor and sensory
impairments are defined in the report published by British Association of Perinatal Medicine in 2008.38
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in
preterm infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
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TABLE 3 Outcomes at discharge to home
Outcome from trial entry
to discharge home
Faster feed
increment group
(30ml/kg/day)
(N= 1394)
Slower feed
increment group
(18ml/kg/day)
(N= 1399)
Unadjusted
effect
measure (CI)a,b
Adjusted effect
measure (CI)a,b,c p-valued
Primary discharge outcome
Microbiologically confirmed or
clinically suspected LOS, n/N (%)
414/1389 (29.8) 434/1397 (31.1) 0.96
(0.85 to 1.08)
0.96
(0.86 to 1.07)
0.43
Missing, n 5 2
NEC (Bell’s stage 2 or 3), n/N (%) 70/1394 (5.0) 78/1399 (5.6) 0.90
(0.66 to 1.24)
0.88
(0.68 to 1.16)
0.37
Missing, n 0 0
Secondary outcome
Death before discharge, n/N (%) 60/1392 (4.3) 65/1393 (4.7) 0.92
(0.59 to 1.45)
0.91
(0.55 to 1.53)
0.65
Missing, n 2 6
Time taken to reach full milk
feeds (days) (145 ml/kg/day for
3 consecutive days), median (IQR)
and median difference (99% CI)
7 (7–10) 10 (9–13) –3.0
(–3.3 to –2.7)
–2.7
(–3.1 to –2.4)
< 0.001
Missing, n 72 102
Weight SD score at discharge
home,d mean (SD) and mean
difference (99% CI)
–1.5 (1.1) –1.5 (1.1) –0.04
(–0.15 to 0.08)
–0.02
(–0.11 to 0.08)
0.67
Missing, n 75 77
Head circumference SD score at
discharge home,d mean (SD) and
mean difference (99% CI)
–0.8 (1.5) –0.7 (1.7) –0.09
(–0.27 to 0.09)
–0.07
(–0.24 to 0.10)
0.31
Missing, n 258 228
Duration of parenteral feeding (days)
from trial entry to discharge home,
median (IQR) and median difference
(99% CI)
9 (7–14) 11 (9–16) –2.0
(–2.4 to –1.6)
–2.2
(–2.7 to –1.6)
< 0.001
Length of time in intensive care
(days) from trial entry to discharge
home, median (IQR) and median
difference (99% CI)
7 (4–21) 8 (4–21) –1.0
(–2.6 to 0.6)
–0.4
(–1.5 to 0.6)
0.30
Length of hospital stay (days) from
trial entry to discharge home,e
median (IQR) and median
difference (99% CI)
54 (37–81) 55 (38–78) –1.0
(–5.2 to 3.2)
0.1
(–1.9 to 2.0)
0.94
Missing, n 62 71
a Risk ratios for binary outcomes.
b 95% CIs for LOS and NEC (Bell’s stage 2 or 3) (primary outcomes). 99% CIs for all other outcomes
(secondary outcomes).
c Adjusted for minimisation factors: collaborating hospital, single or multiple birth, gestational age at birth and
birthweight of < 10th centile for gestational age where technically possible.
d Calculated using the British 1990 growth reference (revised September 2009).46 The SD scores indicate how far an
infant is from the population mean weight and head circumference for infants of the same age and sex. So, for
example, infants with a SD score of –2 or below compare approximately with the bottom 2% of the reference population.
e Surviving infants only.
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in
preterm infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
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Primary outcome
Data were available for 2470 infants (88%) at 24 months of age CGA. In the faster increment group,
802 out of 1224 (65.5%) infants survived to 24 months of age CGA without moderate or severe
disability, compared with 848 out of 1246 (68.1%) infants in the slower increment group [adjusted
risk ratio (ARR) 0.96, 95% CI 0.92 to 1.01]. There were also no significant differences in the separate
components of the composite outcome, with survival occurring in 1326 out of 1394 (95.1%) infants in
the faster increment group and 1322 out of 1399 (94.5%) infants in the slower increment group, and
moderate or severe disability in 354 out of 1156 (30.6%) infants in the faster increment group and 321
out of 1169 (27.5%) infants in the slower increment group.
Secondary outcomes at 24 months of age corrected for gestational age
For one of the components of the definition of moderate or severe neurodevelopmental disability at
24 months CGA, there was evidence of a significant difference between groups after adjustment for the
factors used in the minimisation algorithm. Moderate or severe motor impairment occurred in 87 out
of 1164 (7.5%) infants in the faster increment group and 59 out of 1177 (5.0%) infants in the slower
increment group (ARR 1.48, 99% CI 1.02 to 2.14; p = 0.007) (see Table 2).
There was, however, no evidence of a significant difference between groups in the other three
components of the disability definition (moderate or severe visual, hearing or cognitive impairment).
However, numerically more adverse outcomes were seen in the faster increment group for each of
these components; this was also the case for the diagnosis of cerebral palsy by a doctor or other
health professional, which occurred in 5.4% of the faster increment group and 3.2% of the slower
increment group (ARR 1.66, 99% CI 0.97 to 2.84; p = 0.015).
Other secondary outcomes
In total, 414 out of 1389 (29.8%) infants in the faster increment group had microbiologically confirmed
or clinically suspected LOS, compared with 434 out of 1397 (31.1%) infants in the slower increment
group (ARR 0.96, 95% CI 0.86 to 1.07; p = 0.43). Bell’s stage 2 or 3 NEC occurred in 70 out of 1394
(5.0%) infants in the faster increment group and 78 out of 1399 (5.6%) infants in the slower increment
group (ARR 0.88, 95% CI 0.68 to 1.16; p = 0.37) (see Table 3).
The faster increment group reached full milk feeds significantly sooner: median 7 days from trial entry
(IQR 7–10 days), compared with 10 days (IQR 9–13 days) in the slower increment group (adjusted
median difference –2.7 days, 99% CI –3.1 to –2.4 days; p < 0.001). Significantly fewer days of
parenteral nutrition from trial entry were seen in the faster increment group: 9 days (IQR 7–14 days),
compared with 11 days (IQR 9–16 days) in the slower increment group (adjusted median difference
–2.2 days, 99% CI –2.7 to –1.6 days; p < 0.001).
There was no evidence of between-group differences for (1) death during hospitalisation, (2) weight
and head circumference SD scores at discharge home, (3) duration of time in intensive care from trial
entry or (4) duration of hospital stay from trial entry (see Table 2).
Subgroup analyses
A subgroup analysis showed a significant interaction (p = 0.045) with the primary outcome for the type
of enteral milk received: human, formula or both (Figure 2). No significant interaction was seen with the
primary outcome for completed weeks of gestation at birth (p = 0.076) or birthweight < 10th centile
or ≥ 10th centile for gestational age (p = 0.18). A post hoc analysis was also undertaken to assess the
interaction of the presence of absent or reversed antenatal umbilical Doppler studies with the two
incremental feed rates (see Tables 4 and 5).
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The subgroup analyses did not show any significant interactions with NEC (Figure 3) for:
l completed weeks of gestation at birth (p = 0.63)
l birthweight < 10th centile or ≥ 10th centile for gestational age (p = 0.25)
l the type of enteral milk received (human, formula or both) (p = 0.53)
l the presence of absent or reversed antenatal umbilical Doppler studies (p = 0.09). This was a post
hoc analysis.
The subgroup analyses did not show any significant interactions with confirmed or suspected LOS
(Figure 4) for:
l completed weeks of gestation at birth (p = 0.07)
l birthweight < 10th centile or ≥ 10th centile for gestational age (p = 0.51)
l type of enteral milk received (human, formula or both) (p = 0.56)
l presence of absent or reversed antenatal umbilical Doppler studies (p = 0.16). This was a post
hoc analysis.
Adjusted risk ratios (faster/slower) and p-values for an interaction between allocation and presence of
absent or reversed antenatal umbilical Doppler studies are shown in Tables 4 and 5.
Faster feed
increment (n/N)
Slower feed
increment (n/N)Subgroup Risk ratio (95% CI)
Gestational age
< 24 weeks
24+0 to 24+6 weeks
25+0 to 25+6 weeks
26+0 to 27+6 weeks
28+0 to 29+6 weeks
30+0 to 31+6 weeks
≥ 32 weeks
Birthweight
Type of milk
Breast only
Mixed
Formula only
< 10th centile
≥ 10th centile
9/29
25/65
46/93
174/267
249/349
247/351
52/70 52/78
300/368
236/330
179/282
43/93
32/66
6/29
166/256 162/259
636/968 685/986
12/30 28/40
558/839
231/352 248/377
572/827
0.25 0.5 1
Slow better Fast better
2 4
0.045
0.182
p-valuea
0.076
1.50 (0.62 to 3.63)
0.79 (0.57 to 1.11)
1.07 (0.82 to 1.40)
1.03 (0.89 to 1.19)
1.00 (0.90 to 1.10)
0.86 (0.79 to 0.94)
0.95 (0.89 to 1.00)
0.96 (0.89 to 1.02)
0.59 (0.38 to 0.91)
1.13 (0.90 to 1.41)
1.04 (0.92 to 1.17)
1.01 (0.91 to 1.12)
FIGURE 2 Subgroup analyses for survival without moderate or severe disability to 24 months of age CGA. n/N refers
to the number of infants with the primary outcome/number of infants in that category. a, The primary outcome was
survival without moderate or severe neurodevelopmental disability (CGA). p-values for interaction were adjusted for
minimisation factors: collaborating hospital, single or multiple birth, gestational age at birth, and whether or not the
birthweight was below the 10th percentile for gestational age, when technically possible. p-values and CIs were not
adjusted for multiple comparisons and should not be used to infer definitive treatment effects. Adapted from New
England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in preterm infants.
N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
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Breast only
Mixed
Formula onlyc
Type of milk
< 10th centile
≥ 10th centile
Birthweight
Gestational age
Subgroup Fast (n/N)a Slow (n/N)a Risk ratio (95% CI) p-value
Fast better Slow better
< 24 weeks
24+0 to 24+6 weeks
25+0 to 25+6 weeks
26+0 to 27+6 weeks
28+0 to 29+6 weeks
30+0 to 31+6 weeks
≥ 32 weeksb
28/381
42/964
0/46
30/391
46/959
1/47
14/295
56/1099
20/291
58/1107
6/30
11/72
18/103
21/291
12/377
2/432
0/89
8/31
10/69
9/101
26/297
17/383
7/432
1/86
0.25 0.5 1 2 4
1.04 (0.66 to 1.66)
0.83 (0.55 to 1.25)
0.65 (0.35 to 1.21)
0.97 (0.72 to 1.30)
0.78 (0.36 to 1.67)
1.03 (0.45 to 2.32)
1.75 (0.68 to 4.53)
0.84 (0.55 to 1.29)
0.72 (0.29 to 1.81)
0.25 (0.05 to 1.22)
0.533
0.249
0.631
FIGURE 3 Subgroup analyses for NEC from trial entry to discharge from hospital. a, n/N refers to the number of infants
with one or more episodes of NEC from trial entry to hospital discharge/number of infants in that category. b, Combined
with the 30+0 to 31+6 weeks’ category for calculation of RR. c, Combined with mixed category for calculation of RR.
ARRs (faster/slower) and p-values for an interaction between allocation and category are shown. Adapted from
New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in preterm infants.
N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
Formula only
Mixed
Breast only
Type of milk
< 10th centile
≥ 10th centile
Birthweight
Gestational age
Subgroup Fast (n/N)a Slow (n/N)a Risk ratio (95% CI) p-value
Fast better Slow better
< 24 weeks
24+0 to 24+6 weeks
25+0 to 25+6 weeks
26+0 to 27+6 weeks
28+0 to 29+6 weeks
30+0 to 31+6 weeks
≥ 32 weeks
11/46 7/47
112/380
289/961
118/390
308/958
87/290
347/1106
91/293
323/1096
2/89
46/432
21/30 24/31
40/69
63/100
138/297
95/382
66/432
8/86
51/71
68/101
135/290
91/376
0.25 0.5 1 2 4
0.562
0.510
0.073
0.94 (0.73 to 1.20)
1.17 (0.92 to 1.49)
1.04 (0.84 to 1.30)
1.00 (0.87 to 1.16)
0.99 (0.78 to 1.26)
0.71 (0.47 to 1.07)
0.23 (0.05 to 1.13)
0.94 (0.83 to 1.07)
0.98 (0.79 to 1.22)
0.98 (0.83 to 1.04)
1.53 (0.62 to 3.78)
1.02 (0.84 to 1.22)
FIGURE 4 Subgroup analyses for confirmed or suspected LOS from trial entry to discharge from hospital. a, n/N refers to the
number of infants with one or more episodes of LOS from trial entry to hospital discharge/number of infants in that category.
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in preterm
infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
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Safety and adverse events
Sixty-two SAEs were reported, including follow-up reports, relating to 52 separate incidents. Of these
52 events, 34 were not related or relevant to the trial. Fourteen were deemed ‘possibly’ related, but
were listed in the protocol as expected SAEs.33
Four SAEs were deemed ‘possibly’ trial related and were not on the list of expected SAEs. All were
reported to the Research Ethics Committee (REC), the DMC and the TSC in previous communications.
These four SAEs were two cases of intracardiac thrombosis, one case of prolonged conjugated jaundice
and one case of dehydration when a central venous line extravasated. Table 6 summarises the reported
adverse events (definitions of adverse reactions and events are presented in Appendix 6).
Post hoc analyses
Post hoc exploratory analyses did not show any differential effects of the faster or slower feeding
increments (see Tables 4 and 5).
TABLE 4 Necrotising enterocolitis from trial entry to discharge home by absent or reversed end diastolic flow in the
umbilical arteries (post hoc analysis)
Necrotising
enterocolitis
Faster feed increment group
(30ml/kg/day) (N= 1394)
Slower feed increment group
(18ml/kg/day) (N= 1399)
Adjusted relative
risk (95% CI)
Absent or reversed end diastolic flow in the umbilical arteries identified, n/N (%)
No 62/1163 (5.3) 62/1154 (5.4) 1.00 (0.73 to 1.35)
Yes 8/209 (3.8) 16/226 (7.1) 0.49 (0.23 to 1.06)
Unknown 22 19
Test for interaction p-value from adjusted model= 0.09.
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in
preterm infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
TABLE 5 Confirmed or suspected LOS from trial entry to discharge home by absent or reversed end diastolic flow in the
umbilical arteries (post hoc analysis)
Late-onset sepsis
Faster feed increment group
(30ml/kg/day) (N= 1394)
Slower feed increment group
(18ml/kg/day) (N= 1399)
Adjusted relative
risk (95% CI)
Absent or reversed end diastolic flow in the umbilical arteries identified, n/N (%)
No 337/1159 (29.1) 361/1152 (31.3) 0.94 (0.84 to 1.05)
Yes 69/208 (33.2) 66/226 (29.2) 1.10 (0.89 to 1.36)
Unknown 27 1
Test for interaction p-value from adjusted model= 0.16.
Adapted from New England Journal of Medicine, Dorling et al.45 Controlled trial of two incremental milk-feeding rates in
preterm infants. N Engl J Med 2019;381:1434–43. Copyright © 2019 Massachusetts Medical Society.
TABLE 6 List of SAEs reported by randomisation group
Group Age at SAE (days) Brief description of event Severity Related to trial
Faster increment group
(30 ml/kg/day) (n = 1394)
55 Intracardiac thrombus,
superior vena cava occluded;
deteriorating renal function
Moderate Possibly
52 Infant developed prolonged
conjugated jaundice
Moderate Possibly
Slower increment group
(18 ml/kg/day) (n = 1399)
36 Intracardiac thrombus Moderate Possibly
9 Central venous line extravasated,
dehydration and lack of fluids
Mild Possibly
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Chapter 4 Economic evaluation
Parts of this chapter have been reproduced and adapted from Tahir et al.
47 This is an open access
article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any
purpose, provided the original work is properly cited, a link to the licence is given, and indication of
whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The text includes
minor additions and formatting changes to the original text.
Introduction
This chapter reports the economic evaluation conducted as part of SIFT. The objective of the economic
evaluation was to compare the relative cost-effectiveness of two rates of enteral feed advancement,
faster feed increments (30 ml/kg/day) with slower feed increments (18 ml/kg/day), on the principal
outcome of survival without moderate or severe disability at 24 months of age CGA.
Methods
A within-trial cost-effectiveness analysis (CEA) was performed from the perspective of the NHS and
Personal Social Services (PSS) in line with recommended practice.48 The CEA results are expressed in
terms of additional cost per survivor without disability at 24 months of age CGA.
Outcomes
The primary outcome of the CEA was disability-free survival at 24 months of age CGA. Secondary
outcomes of the trial included microbiologically confirmed or clinically suspected LOS and NEC. These
secondary clinical outcomes are presented here as part of a cost–consequence analysis (CCA). All
statistical analyses were conducted in Stata® version 15 (StataCorp LP, College Station, TX, USA).
Data
Resource use and costs
Under the NHS and PSS perspective, only the direct costs to the health service provider incurred
within the time horizon of the trial were included. Costs incurred during the initial hospital stay and
interactions associated with the health service from discharge home to 24 months of age (CGA) were
also included. Resource use data were collected prospectively from centres participating in the trial.
All centres completed a total of eight different data collection forms that included specific items
measuring health-care use. Where SAEs were reported, the associated resource use was collected on
an additional form by the relevant participating centres. For instance, the severity of the event and
any subsequent additional hospitalisation were recorded, as well as the use of concomitant medication.
Health service use until 24 months of age (CGA) was measured through a parent questionnaire (URL:
www.npeu.ox.ac.uk/downloads/files/sift/SIFT%202%20Year%20Form%20-%20V2_21%20Sept%202015.pdf;
accessed 7 March 2019), which included health-care-related resource use items such as use of primary
care services and hospital readmissions.
We also measured out-of-pocket costs to families during the 2-year follow-up period to capture the
broader costs that were associated with each trial group, which had the purpose of presenting an
additional analysis from a wider perspective. The parent questionnaire included specific items measuring
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personal financial costs, such as purchasing special equipment, home changes and the travel costs resulting
from hospital or outpatient visits. Indirect non-medical costs, referring to income or productivity loss,
were also collected. These included both paid and unpaid time off work as a result of the infant’s health.7
This was valued by multiplying the gross wage rate with the time lost (measured in days) as a result of
the infant’s health.
Valuation of resource use
‘Top-down’ methods of costing were used to value resource use. Aggregate cost data were taken from
standard published sources to assign costs to resource use variables such as inpatient days. Relevant
unit costs were obtained from several sources, but predominantly NHS Reference Costs 2017/1849 and
the most recently published Unit Costs of Health and Social Care.50 Medication prices were extracted
from the British National Formulary (BNF)51 and some unit costs were also extracted from existing
literature in this area.52,53 Unit costs were then combined with resource volumes in order to calculate
the costs of health service use for each feeding allocation. Table 7 presents the relevant items of
resource use, their associated unit costs and the source from which these costs were obtained. All
costs were expressed in Great British pounds (GBP) and in 2016–17 prices. Costs were inflated where
necessary, using the Hospital and Community Health Services Pay and Prices Index.50
TABLE 7 Unit costs of resource items (2016–17 pricesa)
Resource use items Unit cost (£)a Source
Intervention
Cost per day on parenteral nutrition 45.00 Walter et al.55
Intensive care: cost per day in intensive care differentiated by level of care required
Level 1: intensive care 1295.00 NHS Reference Costs 2017/1849
Level 2: high-dependency care 1032.00
Level 3: special care 510.00
Initial hospital stay
Cost per pulmonary haemorrhage 1485.00 NHS Reference Costs 2017/1849
Cost per intraventricular haemorrhage by severity
Grade 1 IVH/germinal matrix haemorrhage 862.00 NHS Reference Costs 2017/1849
Grade 2 IVH 1472.00 NHS Reference Costs 2017/1849
Grade 3/4 IVH 1519.00 NHS Reference Costs 2017/1849
Course of shunts for hydrocephalus 2608.00 NHS Reference Costs 2017/1849
Bronchopulmonary dysplasias 5954.00 NHS Reference Costs 2017/1849
Periventricular leukomalacias 1341.00 NHS Reference Costs 2017/1849
Retinopathy treated medically or surgically 1603.00 NHS Reference Costs 2017/1849
Patent ductus arteriosus treated with NSAID 1152.00 BNFC56
Surgeries due to gut signs 6629.00 NHS Reference Costs 2017/1849
Cost of antibiotic medication per day 3.00 BNFC56
Cost of antifungal treatment per day 1.06 BNFC56
Cost per ml of preterm milk formula 0.02 Ganapathy et al.52
Cost per packet of breast milk fortifier 0.93 Ganapathy et al.52
Cost per litre of donor breast milk 335.00 Renfrew et al.53
Cost per 200 ml of term formula milk 2.00 Renfrew et al.53
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Economic analysis
A CCA was conducted as a preliminary measure to compare the disaggregated costs with the
outcomes for both feeding increments. CCA is a form of economic evaluation where disaggregated
costs and outcomes (consequences) are presented in their natural units.57 To calculate costs, the
quantity of resource use per infant was multiplied by unit costs. Mean costs per infant were estimated
and the mean cost differences between the two feeding allocations were calculated. To address the
skewness often present in cost data, a bootstrapping approach58 was carried out to calculate CIs
around the mean costs. If the CIs of the difference in mean resource use and the costs between groups
do not cross zero, this indicates a significant difference. In bootstrapping, repeated random samples of
the same size as the original sample are drawn with replacement from the data.58 The statistic of
interest (mean) is calculated from each resample and these bootstrap estimates of the original statistic
are then used to build up an empirical distribution for the statistic.58
The primary base-case economic analysis took the form of a CEA from the perspective of the NHS
and PSS. A CEA is a method for assessing the gains in health relative to the costs of different health
interventions.59 In the current study, health consequences are measured as a clinical outcome rather
than in the form of health-related utilities, such as quality-adjusted life-years (QALYs). An incremental
analysis was conducted, comparing incremental (additional) costs with the outcomes between the two
feeding allocations. Costs and clinical outcomes associated with each feeding allocation were combined
by calculating incremental cost-effectiveness ratios (ICERs). An ICER is expressed as the incremental
cost (£) per incremental gain in a natural unit.60 Cost data were discounted at 3.5% but discounting is
not applied to outcomes in natural units; thus, outcomes were not discounted. Cost-effectiveness was
based on the principal outcome of additional cost per survival without moderate to severe disability at
24 months of age CGA and from the perspective of the NHS and PSS.
The cost-effectiveness estimates are presented on a cost-effectiveness plane, to illustrate the
incremental cost and effect of the intervention (faster feed increments). The cost-effectiveness plane
TABLE 7 Unit costs of resource items (2016–17 pricesa) (continued )
Resource use items Unit cost (£)a Source
Resource use during 2-year follow-up
Cost per outpatient day 199.00 NHS Reference Costs 2017/1849
Cost per inpatient day 635.00 NHS Reference Costs 2017/1849
Cost per operation 2247.00 NHS Reference Costs 2017/1849
Cost per general practitioner visit 33.00 PSSRU50
Cost per health visitor visit 75.00 PSSRU50
Cost per community nurse visit 36.00 PSSRU50
Cost per home visitor/volunteer visit 19.00 PSSRU50
Cost per community paediatrician visit 407.00 NHS Reference Costs 2017/1849
Cost per physiotherapist visit 95.00 NHS Reference Costs 2017/1849
Cost per social worker visit 39.00 PSSRU50
Cost per speech and language therapist visit 95.00 NHS Reference Costs 2017/1849
Cost per dietitian visit 85.00 NHS Reference Costs 2017/1849
Cost per other health-care professional visit 135.00 NHS Reference Costs 2017/1849
BNFC, British National Formulary for Children; IVH, intraventricular haemorrhage; NSAID, non-steroidal anti-inflammatory
drug; PSSRU, Personal Social Services Research Unit.
a Prices are inflated to 2016–17 costs using the UK Hospital and Community Health Services Pay and Prices Index.54
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has four quadrants, each with a different implication for the decision of implementing the intervention.61
This was used to determine the relative position of the results. For example, faster feed increments
might be said to ‘dominate’ slower feed increments if its position on the plane showed that the cost of
the intervention was lower and the effectiveness in achieving the outcome was greater, when compared
with slower feed increments. In other words, if faster feed increments were cheaper and more effective
than slower feed increments, faster feed increments would be said to dominate.
Sensitivity analysis
Statistical uncertainty around the difference in ICERs was estimated by 5000 bootstrap replications,
represented as scatter points on the cost-effectiveness plane. Results were presented using cost-
effectiveness acceptability curves (CEACs) to reflect sampling variation and uncertainties in the
cost-effectiveness value where appropriate. A CEAC shows the probability that an intervention
(e.g. faster feed increments) is cost-effective compared with the alternative (e.g. slower feed increments)
given the observed data, for a range of maximum monetary values (thresholds) that decision-makers
might be willing to pay for a particular unit change in outcome.61 Unlike economic evaluations, in which
outcomes are expressed in QALYs, there is no set monetary threshold here for the primary outcome.
Therefore, we examined cost-effectiveness at a range of monetary willingness-to-pay (WTP) thresholds
(£0 to £40,000 per additional prematurity-adjusted survivor without disability at 24 months).
To explore the cost of missing resource use data for those infants who did not complete follow-up
(15.4%), multiple imputation was performed. Multiple imputation replaces each missing observation
with a set of plausible imputed (predicted) values, drawn from the posterior predictive distribution of
the missing data given the observed data.62 Because the missing values are replaced with predicted
values, calculated in this way, this method is more favourable than simpler methods, such as replacing
missing values with the means of all available values. Costs were imputed at the total cost level and
the imputation model used 500 imputations.
Results
Participants
In total, 2804 infants were recruited into the trial, of whom 1400 were randomised to faster feed
increments and 1404 were randomised to slower feed increments. Consent was withdrawn for six
infants in the faster increment group and for five infants in the slower increment group. A total of
129 deaths occurred before discharge home during infants’ initial hospital stay. Of these deaths,
62 occurred in the faster increment group and the remaining 67 were in the slower increment group.
Follow-up rates at 24 months CGA in survivors were 84.3% (1175 infants) and 85.0% (1189 infants) in
the faster increment group and slower increment group, respectively.
Resource use
Average volumes of resource use per infant during the initial hospital stay and the 2-year follow-up
are presented in Table 8. On average, infants receiving slower feed increments spent more days in
intensive care and in hospital. There was very little variation in resource use during the initial hospital
stay across a number of variables, including number of surgeries owing to gut signs or intracranial
abnormalities.
For the follow-up data, there was very little variation in mean resource use between groups. Infants
who had received faster feed increments reported a slightly higher number of days as inpatients,
community nurse visits, physiotherapist visits and health visitor visits than the slower feed increment
group did.
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TABLE 8 Mean resource use across treatment groups
Resource items
Faster feed increment
group (N= 1394),
mean (SD)
Slower feed increment
group (N= 1399),
mean (SD)
Bootstrap difference,
adjusted mean
difference (95% CI)
Days receiving faster or slower feed
increments
13.24 (16.22) 15.04 (14.31) –1.80 (–2.87 to –0.55)a
Days in intensive care
Level 1: intensive care 15.06 (18.43) 14.72 (17.48) 0.34 (–0.96 to 1.71)
Level 2: high-dependency care 20.71 (24.79) 21.12 (19.65) –0.41 (–1.96 to 1.51)
Level 3: special care 30.13 (15.28) 29.60 (15.05) 0.53 (–0.58 to 1.68)
Initial hospital stay
Days in hospital 91.00 (94.77) 94.44 (103.76) –3.25 (–11.07 to 3.30)
Grade 1 IVH/germinal matrix haemorrhage,
proportion of daysa
0.15 (0.38) 0.16 (0.44) –0.01 (–0.04 to 0.02)
Grade 2 IVH, proportion of days 0.10 (0.36) 0.09 (0.34) 0.006 (–0.02 to 0.03)
Grade 3 IVH, proportion of days 0.04 (0.25) 0.03 (0.25) 0.007 (–0.01 to 0.02)
Grade 4 IVH, proportion of days 0.04 (0.24) 0.03 (0.25) 0.007 (–0.02 to 0.02)
Shunts for hydrocephalus, proportion of days 0.01 (0.13) 0.01 (0.18) –0.002 (–0.02 to 0.009)
Bronchopulmonary dysplasias, proportion of
days
0.32 (0.89) 0.31 (0.90) 0.01 (–0.04 to 0.06)
Periventricular leukomalacias, proportion of
days
0.03 (0.27) 0.02 (0.20) 0.009 (–0.006 to 0.02)
Retinopathies treated medically or surgically,
proportion of days
0.07 (0.36) 0.06 (0.32) 0.02 (–0.002 to 0.04)
PDA treated with NSAID or surgery,
proportion of days
0.16 (0.49) 0.17 (0.47) –0.001 (–0.03 to 0.03)
Surgeries as a result of gut signs, proportion
of days
0.04 (0.25) 0.04 (0.23) 0.001 (–0.02 to 0.02)
Days on antibiotic medication 5.60 (11.13) 5.55 (10.85) 0.05 (–0.70 to 0.10)
Days treated with antifungals 1.20 (5.90) 1.59 (7.52) –0.39 (–0.86 to 0.10)
Days receiving preterm milk formula 1.74 (3.93) 1.88 (4.14) –0.14 (–0.44 to 0.15)
Days receiving breast milk fortifier 0.86 (2.47) 0.83 (2.45) 0.02 (–0.19 to 0.20)
Days receiving donated breast milk 1.35 (3.34) 1.43 (3.67) –0.12 (–0.41 to 0.11)
Days receiving term formula milk 0.24 (1.35) 0.24 (1.57) –0.001 (–0.11 to 0.11)
Resource use during 2-year follow-up
Readmissions, proportion of days 0.34 (0.48) 0.34 (0.48) –0.006 (–0.04 to 0.03)
Operations, proportion of days 1.47 (15.71) 1.46 (0.36) 0.02 (–0.99 to 1.10)
Days as an inpatient, proportion of days 3.23 (17.33) 2.82 (11.84) 0.41 (–0.60 to 1.73)
Routine hospital follow-up visits as a day
patient, proportion of days
3.08 (6.82) 3.17 (6.78) –0.1 (–0.59 to 0.41)
Other hospital outpatient visits as a day
patient, proportion of days
0.39 (0.49) 0.37 (0.49) 0.02 (–0.02 to 0.06)
Paediatrician visits as a day patient,
proportion of days
1.55 (3.96) 1.58 (3.57) –0.03 (–0.29 to 0.26)
continued
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Costs
Mean resource use was combined with unit costs (see Table 7) to derive the health service costs
accruing from each feeding strategy (Table 9). Average costs of the initial hospital stay did not differ
very much between the two groups; this is not surprising given that mean resource use was very
similar between groups. Mean costs throughout the 2-year follow-up are also presented in Table 9.
The most sizeable cost difference was in the cost of inpatient stays; this cost £267 more in the faster
increment group. Throughout the follow-up period, health service costs were generally slightly higher
for the faster increment group, particularly for primary care services, such as general practitioner,
health visitor and community nurse visits.
TABLE 8 Mean resource use across treatment groups (continued )
Resource items
Faster feed increment
group (N= 1394),
mean (SD)
Slower feed increment
group (N= 1399),
mean (SD)
Bootstrap difference,
adjusted mean
difference (95% CI)
Number of general practitioner visits 2.68 (6.06) 2.42 (5.60) 0.26 (–0.17 to 0.70)
Number of health visitor appointments 2.05 (6.27) 1.88 (5.86) 0.17 (–0.26 to 0.61)
Number of community nurse visits 2.25 (21.38) 1.28 (6.40) 0.97 (0.10 to 2.36)a
Number of home visitor/volunteer visits 0.05 (0.21) 0.04 (0.20) 0.004 (–0.01 to 0.02)
Number of community paediatrician visits 0.27 (1.46) 0.29 (1.75) –0.01 (–0.14 to 0.11)
Number of physiotherapist visits 2.03 (8.00) 1.93 (8.21) 0.1 (–0.48 to 0.71)
Number of social worker visits 0.22 (2.02) 0.19 (2.46) 0.03 (–0.14 to 0.19)
Number of speech and language therapist visits 0.54 (2.70) 0.53 (2.87) 0.006 (–0.21 to 0.20)
Number of dietitian visits 0.68 (3.47) 0.73 (3.16) –0.05 (–0.27 to 0.21)
IVH, intraventricular haemorrhage; NSAID, non-steroidal anti-inflammatory drug; PDA, patent ductus arteriosus.
a Statistically significant (p < 0.05).
TABLE 9 Disaggregated costs by trial groups (£) (2016–17 prices)
Resource items
Faster feed increment
group (n= 1394),
mean (SD)
Slower feed increment
group (n= 1399),
mean (SD)
Bootstrap difference,
adjusted mean
difference (95% CI)
Days receiving faster or slower feeds 597 (731) 678 (645) –80 (–126 to –30)
Days in intensive care
Level 1: intensive care 19,506 (23,863) 19,063 (22,631) 443 (–1272 to 2277)
Level 2: high-dependency care 21,378 (25,578) 21,798 (20,280) –420 (–2016 to 1566)
Level 3: special care 15,375 (7793) 15,102 (7676) 273 (–315 to 887)
Initial hospital stay
Grade 1 IVH/germinal matrix
haemorrhage, proportion of days
127 (331) 134 (381) –11 (–38 to 15)
Grade 2 IVH, proportion of days 143 (532) 136 (494) 7 (–28 to 46)
Grade 3 IVH, proportion of days 60 (378) 50 (381) 10 (–19 to 40)
Grade 4 IVH, proportion of days 54 (364) 51 (366) 4 (–23 to 30)
Shunts for hydrocephalus, proportion
of days
24 (348) 28 (477) –4 (–40 to 24)
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Mean total costs for each group are presented in Table 10. Faster feed increments cost approximately
£1043 less per infant than slower feed increments during infants’ initial hospital stay; however, within
the 2-year follow-up the faster increment group was more costly by approximately £349 per infant.
Overall, the intervention of faster feed increments was less costly.
Mean total costs
Mean total costs are detailed in Table 10.
TABLE 9 Disaggregated costs by trial groups (£) (2016–17 prices) (continued )
Resource items
Faster feed increment
group (n= 1394),
mean (SD)
Slower feed increment
group (n= 1399),
mean (SD)
Bootstrap difference,
adjusted mean
difference (95% CI)
Bronchopulmonary dysplasias,
proportion of days
2475 (3970) 2392 (4112) 83 (–214 to 362)
Periventricular leukomalacias,
proportion of days
48 (305) 36 (240) 12 (–7 to 32)
Retinopathies treated medically or
surgically, proportion of days
137 (499) 103 (453) 35 (–1 to 70)
PDA treated with NSAID or surgery,
proportion of days
202 (509) 202 (537) 0.58 (–37 to 43)
Surgeries as a result of gut signs,
proportion of days
237 (1567) 231 (1536) 5 (–116 to 114)
Days on antibiotic medication 16 (33) 16 (32) 0.16 (–2 to 3)
Antifungals 1 (6) 2 (8) –0.41 (–0.89 to 0.14)
Preterm milk formula 0.04 (0.08) 0.04 (0.09) –0.003 (–0.009 to 0.004)
Breast milk fortifier 0.79 (2) 0.78 (2) 0.02 (–0.17 to 0.20)
Donated breast milk 438 (1120) 480 (1232) –41 (–127 to 51)
Term formula milk 0.37 (2) 0.37 (2) –0.001 (–0.19 to 0.15)
Resource use during 2-year follow-up
Number of operations 3316 (35,294) 3273 (29,567) 42 (–2259 to 2612)
Number of inpatient stays 2150 (11,057) 1883 (7577) 267 (–326 to 1076)
Number of outpatient visits 1067 (1971) 1082 (1827) –18 (–162 to 112)
Number of general practitioner visits 88 (200) 80 (185) 9 (–6 to 24)
Number of health visitor appointments 154 (471) 141 (440) 13 (–23 to 45)
Number of community nurse visits 81 (770) 46 (230) 35 (5 to 94)
Number of home visitor/volunteer visits 0.86 (4) 0.77 (4) 0.09 (–0.20 to 0.40)
Number of community paediatrician
visits
112 (596) 117 (712) –6 (–59 to 39)
Number of physiotherapist visits 193 (760) 183 (780) 9 (–55 to 61)
Number of social worker visits 9 (79) 8 (96) 1 (–6 to 7)
Number of speech and language
therapist visits
51 (257) 50 (273) 0.59 (–19 to 18)
Number of dietitian visits 58 (295) 62 (269) –4 (–23 to 19)
IVH, intraventricular haemorrhage; NSAID, non-steroidal anti-inflammatory drug; PDA, patent ductus arteriosus.
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Cost–consequence analysis
The disaggregated CCA results (Table 11) show that the faster feed increment (the intervention) was
slightly more costly and also less effective in terms of achieving the primary outcome of survival
without moderate or severe neurodevelopmental disability at 24 months of age CGA.
The total estimated costs of health service use for the first 2 years after birth were approximately
£134.5M for those allocated faster feed increments compared with £136.6M for those allocated
slower feed increments. In Table 11, total costs are broken down into mean costs during initial hospital
stay and during follow-up for both groups. Although there were fewer deaths in the faster feed
increment group, for the primary outcome of survival without moderate or severe neurodevelopmental
disability at 24 months (CGA), the intervention (faster feed increment) was less effective than the
comparator (slower feed increment). Increasing milk feeds at a faster rate was associated with
46 (2.6%) more infants with moderate to severe disability compared with the slower feed group.
The breakdown of costs shows that faster feed increments compared with slower feed increments
are less costly on average during infants’ initial hospital stay, and the 2-year follow-up data show
TABLE 10 Mean total costs (£) (2016–17 prices)
Cost category
Faster increments (n= 1224) Slower increments (n= 1246)
Bootstrap mean
difference (95% CI)Total cost Mean SD Total cost Mean SD
Costs of initial hospital care 124,386,552 101,623a 80,759 126,923,790 101,865 80,498 –242 (–6307 to 6251)
Costs from initial discharge
from hospital up to 24 months
corrected age
10,151,856 8,294 49,585 9,698,864 7,784 38,473 510 (–2864 to 4508)
Total costs of health service
use after initial discharge from
hospital and up to 24 months
corrected age CGA
134,538,408 109,917 98,040 136,623,900 109,650 94,788 267 (–6928 to 8117)
a Mean total costs are calculated as total cost for this category divided by the sample size of the arm.
TABLE 11 Cost–consequence analysis
Costs/consequences
Faster feed group
(N= 1224)
Slower feed group
(N= 1246)
Total costs of health service use for 2 years £134,538,408 £136,623,900
Costs of initial hospital care £124,386,552 £126,923,790
Costs from initial discharge from hospital up to 24 months
of age
£10,151,856 £9,698,864
Survival at hospital discharge, n (%) 1332/1394 (95.6) 1337/1399 (95.2)
Death before discharge home, n (%) 60/1392 (4.4) 65/1393 (4.8)
Disability-free survival at 24 months (corrected for
prematurity), n (%)
802/1224 (65.5) 848/1246 (68.1)
Survival at 24 months (corrected for prematurity), n (%) 1326/1394 (95.1) 1322/1399 (94.5)
Moderate to severe neurodevelopmental disability, n (%) 473/1394 (33.9) 405/1399 (28.9)
Neonatal late-onset invasive infection, n (%) 414/1398 (29.8) 434/1397 (31.1)
Necrotising enterocolitis, n (%) 70/1394 (5) 78/1399 (5.6)
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that during follow-up, costs are lower in the faster feeding group, on average. This is primarily due to
greater resource use associated with those in the faster increment group, in terms of hospital inpatient
stays and primary care visits (see Tables 8 and 9).
Cost-effectiveness analysis
Faster feeds are shown to cost more per infant on average and are also less effective in achieving the
primary outcome, thus they are dominated by the comparator (slower feeds) (see Figure 1). There is
therefore no ICER to present in this circumstance.
Non-health-service costs
Non-health-service costs measured from a broader societal perspective have not been incorporated into
the main results, given that the intervention leads to more cases of disability. Parents’ out-of-pocket
costs were measured and analysed (see Tables 13 and 14).
Sensitivity analysis
The scattered points on the cost-effectiveness plane (Figure 5) show that the vast majority of points lie
in the south-west and north-west quadrants. This shows that at higher monetary thresholds, faster feed
increments become the more expensive strategy but remain less effective. At the higher thresholds
(north west), the existing treatment (slower feed increments) dominates the intervention. This finding
is confirmed by the CEAC (Figure 6), which shows a decreased probability that the intervention is cost-
effective as the WTP threshold increases. This is because the more monetary value that is placed on a
disability-free life, the less we value this intervention, given its detrimental effects for this outcome.
Table 12 shows the mean resource use for all infants once missing data were accounted for using multiple
imputation.When the missing values were accounted for, faster feed increments were slightly more costly
than slower feed increments (£378 more per infant). This is in contrast to the baseline results that showed
the reverse; however, given the poorer clinical outcomes associated with the faster feed increment, this
finding is in line with the expectations.We would expect more resource use in the faster increment group
as a result of more health-care utilisation, for example primary care visits and readmissions.
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FIGURE 5 Cost-effectiveness plane (faster feed increments vs. slower feed increments).
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Discussion
Principal findings
The results of the economic evaluation suggest that for very preterm or VLBW infants, daily
increments in milk volume at a faster increment rate (30 ml/kg) are per infant more costly and less
cost-effective compared with a slower increment rate (18 ml/kg). In terms of initial hospital and
post-discharge costs between the two feeding increment groups evaluated, a faster increment was
shown to be more costly on average compared with feeding with a slower increment at 24 months
corrected age. The average cost per infant for faster increments was £109,917, compared with
£109,650 for slower increments.
However, in terms of the clinical data, faster feed increments were less effective than slower feed
increments in achieving the principal outcome of survival without moderate or severe neurodevelopmental
disability at 24 months of corrected age. Fewer infants in the faster feed increment group (n = 802) than
in the slower feed increment group (n = 848) achieved the primary clinical outcome of survival without
moderate to severe neurodevelopmental disability at 24 months of age CGA.
When the uncertainty around all of the estimates is incorporated into the analysis, the results suggest
that the faster feeding increment is dominated by the slower feeding increment, as it is, on average,
more costly and less effective than the slower increment. The cost-effectiveness plane (see Figure 5)
that incorporates the uncertainty around each point estimate in the results shows that relative to the
comparator the faster feeding increment is likely to be less cost-effective than the slower feeding
increment (with the scatterplot being predominantly to the left of the origin in Figure 5). The CEAC
also shows the low probability of the intervention being cost-effective, which clearly decreases as the
willingness to pay increases. Thus, in summary, for very preterm or VLBW infants, a faster rate of daily
increments in milk volumes (30 ml/kg) was more costly on average at 24 months of age and also less
TABLE 12 Mean resource use calculated with multiple imputation (£) (2016–17 prices)
Cost
Faster feed increment group
(n= 1224), mean (SD)
Slower feed increment group
(n= 1246), mean (SD)
Total costs of health service use after initial
discharge from hospital to 24 months of age
109,410 (92,266) 109,032 (89,763)
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FIGURE 6 The CEAC (faster feed increments vs. slower feed increments).
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effective, with fewer infants achieving the principal outcome of survival without disability, and this result
is supported by analysis of the cost-effectiveness plane and the CEAC.
One of the key principles of a health economic analysis is to maximise the health benefits from and
ensure the most efficient allocation of scarce resources. It is plausible to incur analyses that suggest
that a potentially small decrement in health outcome is acceptable on cost-effectiveness grounds if the
potential cost saving is great enough to more than offset the loss in health outcome and if the saved
resources can be used to better effect elsewhere. However, this interpretation does not apply in the
current analysis owing to the serious uncertainty in a number of areas. First, regarding costs, the
probabilistic cost-effectiveness analysis and in particular, the cost-effectiveness plane suggests that
faster feeds could be either more or less costly, compared with slower feeds. Second, with respect to
the clinical effectiveness, the probabilistic sensitivity analysis represented in the cost-effectiveness
plane (see Figure 5) indicates that a potential risk for harm is associated with the faster feeding
increment relative to the slower feeding increment and that this is based on the uncertainty in the
data at 24 months. Finally, the neurological development of infants at 24 months of age is a serious
outcome on which the smallest decrement can have lifetime consequences and associated costs.63
There are also broader societal consequences that could result from the clinical outcome, namely
productivity loss, stemming from both the time off work and the lost earnings of parents of children
with disabilities.7,64 The trial did not collect resource and outcome data beyond 24 months of age . It is
noteworthy that, although the costs of initial hospital care were lower in those allocated faster feed
increments than in those allocated to slower feed increments and overall lower in the specific period
from initial discharge to the 24 months of age assessment, the costs incurred by those allocated to
faster feeding increments for this period were slightly greater on average than for those allocated to
slower feeding increments.
In summary, based on the neurological outcome at 24 months of age and given the uncertainty in both
the cost and effectiveness, the faster feeding increment (30 ml/kg/day) that was tested in the trial
cannot be advocated on cost-effectiveness grounds.
A secondary analysis that was based on cost per case of neonatal sepsis avoided was initially proposed,
but this was deemed misleading in the final analysis because this is an intermediate outcome only and
does not relate to the ultimate outcome of the infant. Although outcomes in terms of LOS and NEC
were more favourable in the intervention group, these outcomes occurred at one time end point that
was intermediate and one time end point that was ultimately undermined by the 2-year outcome.
Strengths and weaknesses of the study
To our knowledge, this was the first economic evaluation conducted alongside the largest RCT
comparing enteral feeding practices in infants. Economic evidence regarding enteral feeding regimes
prior to this study had been scarce. A previous clinical systematic review65 identified only four RCTs
that compared enteral feed volumes in very preterm and VLBW infants. All reviewed studies had
limited their outcome measures to events prior to discharge home, such as the time taken to advance
to full feeds, NEC, LOS and length of hospital stay. These studies generally had a very short follow-up
period (e.g. 2 weeks)25 or no follow-up period at all.23,31 Given that NEC and LOS are major causes of
late neonatal mortality and long-term neurodevelopmental disability, it is possible that some relevant
consequences were excluded in previous studies given they would not have been captured within short
study durations. Thus, only intermediate health service costs were considered and potentially sizeable
cost consequences accruing in the future were ignored. Furthermore, none of these studies included
economic evaluations; thus, inferences cannot be made regarding the most cost-effective feeding
strategy and uncertainty remains. The SIFT was one of the largest studies of any intervention ever
carried out in the neonatal age group and, thus, there is broad applicability of this economic evaluation,
for both policy and practice.
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The rigorous analysis fills a gap in the literature and provides empirical evidence that shows the
broader economic (as well as clinical) consequences if faster feeding practices were to be adopted.
The effectiveness of feeding practices across a number of outcomes has been evaluated, showing that
although faster feeding increments may be effective in the short term, with reduced NEC and LOS,
the detrimental consequences in terms of impairments may not manifest until after infancy.
One of the key weaknesses of this study is that the follow-up period was only 2 years. Had this been
longer, there would be greater scope for an observation of the economic consequences of parenteral
feeding strategies. In particular, the costs of the disabilities/impairments present and the degree of
differentiation in health service use between the two feeding groups would have been informative.
Our analyses required some pragmatic assumptions, specifically regarding the proportion of milk volume
and antibiotic use during infants’ initial hospital stay. Assumptions were necessary owing to excessive
staff burden in collecting data, as getting precise volumes would have meant recording use of these
items for each individual infant every day (as this would vary day to day). Our assumptions are,
however, validated by existing literature and guidelines, that is antibiotic use is based on the doses that
are recommended in the BNF for Children56 and are not likely to have had a significant effect on the
results. Assumptions were also required for some of the resource use that occurred during follow-up.
For items such as inpatient stays, it was not possible to determine the level of care that had been
received by the infant; thus, when assigning a cost to this variable, a weighted average of costs for
different care episodes was calculated. For infants treated in Scottish and Irish hospitals, we assumed
that costs from English sources such as the NHS Reference Costs 2017/1849 would be reflective and
applicable.
A further potential limitation of this study is the confusion that might arise given the reported clinical
results for the base case, which suggested that the difference in effectiveness between faster feeding
increments and slower feeding increments was not significantly significant. Whereas, the health economics
analysis suggests that faster feeds have broadly equivalent costs but poorer outcome and may be harmful.
This contrasting interpretation of the results relates to a requirement in the recommendations for health
economic analysis to estimate and quantify the uncertainty around the clinical end points (based on
appropriate distributions applied to the CIs surrounding the point estimate and using probabilistic
sensitivity analysis).66,67 This recommended and widely endorsed approach to conducting robust economic
analysis is recognised as potentially challenging and has been widely debated and explained elsewhere.67–69
Meaning of the study
Based on the results of this within-trial economic evaluation, increasing the milk feed volumes at the
faster rate (30 ml/kg/day) in very preterm or VLBW infants does not appear to be a cost-effective
strategy.68
This work highlights an ongoing debate and also reveals the impact of the difference in paradigms
between the statistical approach and the economic approach.68,69
Recommendations for future research
Given that the SIFT was not less effective in terms of lower rates of NEC and LOS, it is important for
future research to investigate the cause of the higher rate of disabilities in the intervention group. The
findings suggest that there is an alternative effect of faster increment feeding strategies that leads to
impairments at a later stage in children in this study. Further randomised trials and examination of
feeding data sets (either existing or prospectively collected) may provide further information.
Supplementary data
Non-health-service costs
Details of non-health-service costs are provided in Table 13.
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TABLE 13 Costs to parent(s)
Cost
Faster feed increment
group (n= 1394),
mean (SD)
Slower feed increment
group (n= 1399),
mean (SD)
Bootstrapped
difference, adjusted
mean difference
(95% CI)
Costs to parents (£)
Transport 63.26 (717.34) 34.63 (164.54) 28.53 (–0.16 to 80)
Home changes 67.79 (1645.65) 196.68 (4915.92) –129 (–451 to 83)
Special equipment 27.21 (318.74) 14.98 (155.62) 12 (–3 to 35)
Other costs 161.07 (5001.13) 58.82 (1150.32) 102 (–73 to 417)
Days taken off work
Number of days off work
Without pay for respondent 6.13 (45.78) 5.66 (48.10) 0.473 (–3 to 4)
With pay for respondent 1.85 (11.27) 3.04 (27.80) –1 (–3 to 0.20)
Without pay for respondent’s partner 1.83 (9.45) 1.78 (7.82) 0.047 (–0.56 to 0.71)
With pay for respondent’s partner 1.89 (12.72) 1.11 (5.50) 0.785 (0.19 to 1.72)
Cost of days taken off work (£)
With pay for respondent 199.60 (1213.74) 327.69 (2995.36) –128 (–311 to 16)
With pay for respondent’s partner 203.69 (1370.55) 119.14 (592.95) 85 (16 to 181)
Total out-of-pocket costs from initial
hospital discharge to 2 years
722.53 (5789.46) 751.94 (5991.44) –29 (–442 to 429)
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Chapter 5 Parental experiences of being
approached to join multiple neonatal clinical
trials: a qualitative study, ‘PARENT’
Background
Complex neonatal care must be underpinned by a strong evidence base. This requires RCTs, often with
enrolment shortly after birth when parents are likely to be extremely anxious and where there may
be concerns about longer-term survival and prognosis. Health-care professionals must weigh up the
additional stress caused to parents by being approached for RCT enrolment against their desire to
support trial recruitment; there are likely to be a range of factors that may affect recruitment.70 Preterm
infants are a vulnerable group because they are unable to consent for themselves and, from an ethics
perspective, proxy decisions about enrolment by parents and health-care professionals should always be
made in the infant’s best interests. The vast majority of parents want to be involved in decisions about
whether or not their infant should participate in a RCT, although it is common for parents to also seek
guidance from health-care professionals.71 Studies of such parents suggest that most feel that they made
well-informed decisions, although there is debate as to whether or not fully informed consent can really
be achieved in this context.72–74 The anticipated level of risk and benefit from each individual RCT has
been established as a key driver of parental desire to consent.75,76 In many large, research-active neonatal
intensive care units (NICUs), it is common for parents to be approached to enrol their infant in more
than one trial or study. This presents important ethical and scientific challenges, many of which have
been outlined in a recent review focused on neonatal practice,77 although similar challenges do exist
in adult intensive care settings.78 To achieve high-quality research that determines best practice of
relevance to these families, it is important for research teams to understand the parental perspective
when planning, designing, conducting and analysing research studies. Where co-enrolment does not
compromise scientific integrity, it might be considered unethical to deny parents the choice of supporting
studies and co-enrolment may also make studies more representative of the populations and questions
that they aim to address.77
Research aim
The aim of this study was to describe the perceptions and experiences of parents of infants who
were approached to participate in at least one UK NIHR collaborative RCT, as well as one or more
additional RCT or observational study. This study was designed to explore the experiences of parents
whose infants had been approached to join either or both of two clinical trials of investigational
medicinal products (CTIMPs), which were both funded by the UK NIHR Health Technology Assessment
(HTA) programme. These trials were (1) the Speed of Increasing milk Feeds Trial (SIFT),1 a non-blinded
trial comparing two different rates of increase in the amount of enteral milk feeds the infant received
and (2) the Enteral Lactoferrin in Neonates (ELFIN) trial that was a double-blinded, placebo-controlled
trial of supplemental enteral bovine lactoferrin (a milk protein) added to milk feeds.39 Both of these
trials recruited preterm infants who were born at < 32 weeks’ gestation and who were free of major
congenital anomalies in the first few days of life. At the development stage of both trials, it appeared
likely that there would be considerable overlap of these two trials, although owing to other factors, in
the end there was in fact minimal overlap during recruitment. However, at all of the three units that
took part in this qualitative study (PARENT), a number of NIHR or local RCTs and/or observational
studies were under way,79,80 including one further HTA-funded RCT, Baby-OSCAR (see www.npeu.ox.ac.uk/
baby-oscar; accessed 9 January 2020). At the time of writing, the Baby-OSCAR trial is still actively
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recruiting preterm infants who were born at < 29 weeks’ gestation and is a double-blinded, placebo-
controlled study of the use of ibuprofen in the treatment of patent ductus arteriosus. We took advice
from parents when planning this study and only sought ethics permission to interview parents whose
infants had joined at least one trial or study, even if they had declined enrolment in other studies or
trials. This meant that we did not approach parents who had declined participation in all of the studies
or trials that they had been offered.
Literature search/review
Where the prospect of enrolment to more than one RCT or study exists, additional medical, practical
and ethical issues arise for parents, clinical staff and research teams.77,81 Large NICUs may be actively
recruiting to several studies at any one time, which may include multicentre collaborative or single-
centre RCTs and observational studies. Recent studies with parents suggest that many are receptive
to being approached to be involved in more than one RCT or study, but this area has not been subject
to detailed qualitative study in the context of multiple RCTs in neonates, despite the importance to
future research progress.82,83 A recent study in a paediatric intensive care unit setting suggested that
co-enrolment does not adversely affect recruitment, but this did not include direct exploration of the
reasons behind parental decision-making.84
Methodology (including any changes to the protocol) and data sources
There were no changes to the original protocol.
Sampling
Parents were recruited when their infant was no longer receiving intensive care and prior to their
infant being discharged home from one of three NICUs in the north of England. We included parents
who had been approached to join at least one RCT that was a CTIMP and one additional RCT or
observational study and who had subsequently consented for their infant to join at least one trial
or study. We used purposive sampling based on actual RCT participation, age and educational or
employment factors in an attempt to reflect a broad range of opinions and experiences. The initial
approach for this study was made by a research nurse who had knowledge of study approaches and
enrolment.
Interviews
We reviewed the existing literature, had discussions with doctors and nurses on a NICU and developed
an initial interview topic guide with the aim of provoking discussion rather than seeking specific
answers. The guide was iterative and flexible, which allowed participants to have space to define the
issues that they regarded as significant and to articulate their experiences in their own words.85 We
estimated that we would need 15–20 interviews to reach thematic saturation, that is the point at
which no new themes emerged from the data, and we reached this after 17 interviews, which was
similar to our previous work with parents of preterm infants.86 Interviews were tape-recorded, lasted
approximately 1 hour and took place in a location convenient for the participants, either in hospital or
in their own home. They were conducted by a single trained qualitative researcher (Judy Richards) who
had experience of interviewing parents of preterm infants but who was not a health-care professional.
Interviews were conducted either shortly before or shortly after the infant was discharged home.
Interview recordings were transcribed verbatim and fully anonymised and participants were offered
the opportunity to read and review the interview transcript.
PARENTAL EXPERIENCES OF BEING APPROACHED TO JOIN MULTIPLE NEONATAL CLINICAL TRIALS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Data analysis
Data analysis was carried out using a thematic approach85 in order to identify patterns of meaning across
our data that are relevant to the conduct of research on a neonatal unit. The interview transcripts were
analysed by two research team members to ensure that there was standardisation of thematic coding.
Significant themes and subthemes were extracted from the data and their inter-relationships were
considered alongside contradictions and overlap that emerged between them. The themes were discussed
and agreed with three members of the research team (Judy Richards, Judith Rankin and Nicholas Embleton)
and we include illustrative quotations for the identified themes. Participants are identified as P1, P2, etc.
Governance
This SIFT received approval from the NRES Committee East Midlands, Nottingham, and this PARENT
substudy received approval from the Office for Research Ethics Committees Northern Ireland:
reference 15/NI/0021, 2 February 2015.
Results
Seventeen semistructured qualitative interviews were carried out with parents. There were eight
parents of twins, eight parents of singletons and one set of triplets. Nine interviews were with
the mother alone, one was with the mother and a grandparent and seven interviews were with
both parents. Interviews took place either in the hospital or at home. Data analysis identified four
overarching themes, which outlined factors that influenced parents’ decisions regarding their infants’
participation in more than one RCT or study.
Theme 1: ‘just another little thing’
The main finding that emerged from the data was that parents did not perceive the enrolment of their
infants in more than one study as a major issue in the context of their infant’s daily medical care
(Box 5). Similarly, the actual number of studies or trials (range 1–5 studies or trials) that their infant
participated in was typically not raised as significant for parents. For the most part, being introduced
to several trials or studies soon after the birth was not seen as problematic. The majority of parents
held a strong belief in the benefits of research and had faith that the health-care professionals caring
for their infant would ensure that trial participation would not compromise care in any way. Parents
generally viewed their infant’s participation in more than one study positively. For parents of some sick
infants where survival was uncertain, trial participation was perceived as a ‘gift’ or a way of making
BOX 5 Research viewed in the context of their infant requiring neonatal intensive care
In the beginning I did feel a bit bombarded, but that is only because I was going through hell and I didn’t
really want to think about anything else. They [trials] have to happen in order for things to develop and for
new procedures and new ways of treating things to work and come into practice full time, so it is necessary.
P1
I yeah, it didn’t bother me being asked. I think because I had been bombarded with so much stuff that day
that it was just kind of ‘it’s another little thing’.
P3
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their infant’s potentially short life matter. A small minority of parents were concerned about perceived
issues that may arise when two trial interventions take place concurrently. However, most often,
parents focused on the daily medical care that their infant was receiving and many forgot about the
trials or studies once they were under way.
Theme 2: information gathering
Most parents focused on the specific details of each individual trial and attempted to gain information in
order to make a decision that was as fully informed as possible (Box 6). Parents preferred a succinct PIL
that provided just enough information in a clear ‘jargon-free’ fashion and also valued the opportunity to
talk through any concerns they had with a health-care professional. On the whole, parents tended not to
They [trials] just weren’t important . . . You were more worried about whether they’d poo’d their nappy,
whether they’d wee’d, you know, or how they were doing with their breathing, whether their oxygen support
had gone down. So, trials were just not even . . .
P11
. . . it was just very small variations in the care they [babies] were going to have already and so we thought
‘oh well if it’s just tiny little things like this’ . . .
P5
At the time, coz it seemed almost certain that she was gonna die, it felt like such a gift because it felt like we
were being given an opportunity for her life to matter . . . We knew that if she were to die, she wouldn’t just
have been our baby who we have loved, she’d made an impact, yeah . . . and for us to have the opportunity
to contribute.
P4
We would have been in a hundred studies, I mean obviously you make a decision about whether it will be
good or bad for [baby] but as long as I was satisfied that you know . . . I was happy for the risk to [baby],
I would have been in a hundred like coz they are doing such an amazing job for these babies and the only
reason they are doing it is to try and make these babies better and when you are in that yourself you just
want to make things better for any other baby that comes after her.
P4
And also how would they know which one [NIHR RCT 1 or RCT 2] was having an effect? That was kind of . . .
and I didn’t sort of voice my concerns to the nurse . . . because I’d sort of made my mind up by that point . . .
I thought that em . . . the RCT 2 one was just one step too far for me personally. I just felt like if they are
messing around with her feeding, the amount of feed and then they are putting something new in as well then
I thought, I do not want that.
P1
Every time they spoke to us about a trial, I’d said, ‘Would it affect their care?’. That was my biggest concern.
I almost did not mind them being part of any trial, as long as it did not change . . . If they changed somehow,
it would not affect their care in the future.
P11
BOX 5 Research viewed in the context of their infant requiring neonatal intensive care (continued)
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seek advice from other parents on the ward but did look for ‘stickers’ found on an infant’s cot or incubator
that signified trial participation. Conversely, others did not read the PIL in detail and simply agreed to
participate, driven largely by feelings of moral obligation to take part in trials for the benefit of future
infants; the perception that their infant was benefiting from past research; or parents’ desire to repay
the health-care professionals for the care their infant was receiving.
BOX 6 Information gathering and the approach of health-care professionals explaining the research
. . . his [health professional] manner certainly helped. I think if somebody had come in and said ‘right we are
doing this trial and we need people’ I would have thought, ‘oh my goodness me, I’m not sure’, but it was
definitely the way he broached it, yeah, absolutely that helped.
P12
You know when he asked he was saying ‘have you had a chance to think about it’ you know he was not
saying ‘I want your decision now’, so it was, yeah it felt like they were not rushing us but they helped us
understand that we needed to make a decision by a certain point you know, coz obviously they had to choose
how to progress her feeds.
P4
Obviously the people who were asking the questions were nice which helps, yeah, they weren’t pushy like, like
I say or anything like that, it was always my decision so . . . coz I think the one person who used to come and
. . . he used to come and talk to us every single day . . . and he was lovely as well, but . . . he just wore normal
clothes . . . but he was dead funny.
P3
I think we did three but – this sounds really awful – I’m not sure of the second one, because you know they
collect the wee and poo . . . and I do not know if that’s just because they collect it for the hospital, or if it’s
something that we have agreed to. So I cannot really remember.
P16
So, we did sign up to it [trial], but then when we came here the other week, they were like, ‘Oh, we need to
do a brain scan’, because it was part of the RCT 3 trial, and I thought, ‘Well, I didn’t know that’. You know?
So, those little things that, kind of came out . . .
P11
Yes to be honest I wasn’t even bothered about reading the information because for me, anything research
wise that can be done to help another baby, because we knew we were ultimately going to lose [other twin
baby] for me it did not matter what she went through as long as it was not going to physically harm her it did
not make any difference me reading the information about what it was about so I actually just turned round
to [nurse] and said ‘yes that’s fine’ and she actually told me to take the information away and read it.
P7
Yes, to be honest at that point, again being under a lot of medication I thought just answer ‘yes’. [Doctor] was
very good, he came back afterwards and said ‘can you remember when we talked?’.
P15
. . . coz the leaflets were very well set out and quite sort of succinct which is quite important when you are in
such a distractible kind of mood constantly.
P5
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Although parents felt that they were given all of the information that they needed regarding each
trial, some parents admitted that they sometimes felt too upset or unwell to fully take in trial details,
especially very soon after the birth of their infant. Indeed, some parents suggested retrospectively that
they could not recall the trial names and did not fully understand the goals of the studies or processes
involved, but none suggested that they had any regrets about the decisions they made. Parents often
used their own names for trials to help them remember specific details of each one (the most common
being the ‘poo and wee trial’).
Parents not only placed importance on the information they received from the PIL but also on the
manner of the health-care professional who initially approached them, an issue that they regarded as
very influential in their decision-making process. They appreciated in particular a friendly and informal,
but confident, approach. The majority of parents said that they would have disliked feeling ‘pressured’
(although most did not say that they felt pressured) into making a decision and always appreciated
being given as much time as feasibly possible to think about the trial implications. Although parents
often could not remember the names, numbers and nature of the trials or studies, they remembered
clearly the health-care professional or researcher who introduced them to a trial and supported
them throughout.
Theme 3: making decisions – ‘weighing up the pros and cons’
Parental decisions around participation were not based on the number of trials or studies, but rather
on the perceived risks of each individual trial that they were asked to join (Box 7). Parents considered
issues such as the well-being of their infant at the time of enrolment, the invasiveness of the trial, the
perceived importance of the trial goals and a number of personal motivational factors. Most parents
acknowledged that it was not possible to make a fully informed decision on behalf of their infant and
so in the absence of certainty they drew on more personal, non-medical risk assessments in order to
make a decision. These included wondering what decision ‘baby’ would make; perceiving that trial
participation would help their infant to get well; welcoming ‘another pair of eyes’ over their infant’s
care; a sense of purpose that helped them to overcome feelings of helplessness; a way of getting their
infant home sooner; and, as mentioned above, a debt of gratitude.
BOX 7 Making a decision to actually participate in a research study
We were talking about [baby’s] little character and just how she arrived, we could not have children and then
she arrived in my tummy and she just arrived at 23 weeks and then she lived after 23 weeks and so we were
just thinking she’s not, she would not, sounds silly, but it feels that she’s not a person who would make that
decision based on fear so we felt that we would make the decision based on hope.
P1
I think what we were trying to do in our head was almost imagine, ‘do we think a slower feeding would be
better than a quicker feeding . . . or do we think she would be better off somewhere in the middle?’ And when
we talked that through, we realised, research doesn’t know so we do not know so we might as well, we cannot
make an informed decision about whether one is better than the other so we might as well put her in
the trial.
P4
You know you should be the one changing and feeding your baby, you should be the main caregiver and
actually your time with them is limited. I think it was just a comfort to know that at least we were doing the
one thing that we could do, we were doing, by allowing [baby on trial] . . .
P6
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Theme 4: saying ‘no’
Although parents were happy to be approached about multiple trials or studies, this did not mean that
they agreed to enrol their infant on all of them (Box 8). Some parents admitted that they felt a degree
of guilt attached to declining participation, largely because they felt that they owed it to future infants to
take part in research. Although very few parents could remember how many trials their infant had
participated in, taking part in several trials did provide perceived justification to refuse future trials, as it
gave the impression to health-care professionals that they had ‘done their bit’. Parents who did say ‘no’ to
a trial were divided in whether or not they felt it necessary to give a reason to justify their decision.
Parents articulated a number of specific reasons for refusing an individual trial; one of the main
reasons concerned the time that they were approached about participation. If parents had a possible
discharge home date for their infant, they were often keen to safeguard this and saw enrolment on a
trial close to discharge as a possible threat to their infant leaving the hospital. In addition, a small
minority of parents were approached when their infant was unwell; in these instances they felt that it
was inappropriate that they had been approached and that hospital notes had not been read properly.
Importantly, parents highlighted that it takes confidence to say ‘no’ to health-care professionals who
are caring for their infant. Some parents were relieved to be supported by nursing staff in their decision
to refuse a trial, whereas others felt that their decision was not initially accepted by health-care
professionals, which left them feeling slightly pressurised and guilty.
The lady at the [hospital] caught me when I was just washing the bottles em after expressing some milk
[laughs] again, very informally, ‘we’ve got a trial, I think [baby] would be perfect for it and it about coming on
a err with a . . . feeding tube‘ em. So again there was a positive light to it because obviously babies don’t come
home with feeding tubes, you have to wait until you know until you know, they are on bottles or on the breast
so I was thinking ‘aah, get her home soon’.
P1
Well they did get on the fast arm of the feeds and we just thought that obviously if they were getting more
milk quicker it wouldn’t be detrimental to them because why would they be doing it? But you do think don’t
you if they are getting more food in their bellies they hopefully will be getting bigger and stronger especially as
they were getting breast milk as well.
P6
Yes. ‘It’s a pair of eyes over the baby’, that’s the way I’m thinking of it as. I thought of it as anyone else, if
she’s under someone else’s care, that someone else looking after my baby, sort of makes you feel – not special
– but a bit more reassured I was thinking of it as . . . I was just like- we did not even know what was
happening, I was just like ‘anything that might actually help her, just do, do, do’.
P9
. . . in my logical mind I knew that I should probably take part in this kind of thing because if people hadn’t
done that 40 or 50 years ago then my babies would not be here now. I thought, ‘It is my duty to think about
the future’.
P13
BOX 7 Making a decision to actually participate in a research study (continued)
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Discussion including the robustness of the results and limitations
Enrolment of preterm infants into more than one RCT is a common challenge on many research-active
neonatal units.77 Previous studies have suggested that this may not be a significant issue for many
parents; however, there are few data or in-depth qualitative studies.75,81,82,87 Our study provides an
in-depth analysis of parental experiences and motivations as well as supporting the idea that enrolment
into multiple studies is not necessarily problematic for most parents. Although most parents offered
complex personal reasons that motivated them to see research in a positive light and subsequently enrol
their infant, others provided important insights into their decision-making and how it made them feel,
including their feelings of guilt or obligation.
BOX 8 Declining to participate in a research study
I think it was because he’d [health professional] probably asked me quite a lot. I felt that there was maybe a
real need from his side, so I think if it had just been a, ‘Yes, that’s fine. Don’t worry about it’, I wouldn’t have
felt guilty, but because it was a, ‘Well, should I speak to your husband?’. And he kept coming back to me. You
know? That’s why I felt guilty. I felt like I was, kind of, letting him down a little bit.
P11
Perhaps I was more wary of doing anything that would hinder her coming home at that stage coz I felt like we
were so close to that final hurdle em, even though she was obviously bigger and stronger, you know . . . I mean
I do feel bad because I know good things will come of the research but I think by that point, we were so close
to just getting her home anyway that I did not want to put a spanner in the works.
P1
. . . a lot of mums would feel like it, and probably couldn’t have the confidence to say ‘I’m gonna just say no’.
I certainly don’t think [name] would, my husband, I don’t think he would kind of say ‘look I want to stop this’.
P15
. . . it felt almost like we’d done our bit, if that make sense.
P18
I think if I’d been asked perhaps for any more than three, maybe like four would have been the limit really,
because I think at that point you just kind of it’s a bit, probably it’s a bit too much. I felt that three was fine
em . . . and in a funny way being offered three trials made it easier to say no to one of them.
P1
I don’t like having to say ‘no’ to people, and I think because, because with the whole study 2 one that we just
talked about, that did make me feel a little bit like, ‘Oh no, what happens if I don’t like the trial and I have to
say no again? Will I feel a bit awkward you know?’.
P11
Yes I think from my own point of view, if I was saying no to a trial, it would have to have been a justified
reason as well, it can’t just have been ‘no I can’t be bothered’ because that is not a reason to say ‘no’. Yeah
from my personal perspective ‘no I can’t be bothered’ is not a reason to say no to research that is potentially
going to help somebody and you have got such a sick baby, there’s potentially thousands of babies before you
who’ve done research which is helping the treatment that your baby is getting, unless it’s going to damage or
disturb your baby’s progress, I personally do not think you have got a right to say ‘no’, but that is purely my
own personal perspective on the situation . . .
P7
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Our study has several strengths. The semistructured nature of the interviews gave parents the space
and time to reflect on their experiences of enrolling their infant on multiple trials and the initial
approach to parents to take part in this qualitative study typically took place several weeks after their
infant was born and enrolled into these studies. Participants were enabled to articulate in their own
words the issues that were important to them. A further strength was the impartial nature of the
qualitative researcher (Judy Richards) who was not a health-care professional, had no prior involvement
in clinical trials and was able to provide valuable insight as a ‘naive observer’. Nevertheless, the findings
of the study require careful interpretation. The design and parameters of the research that may affect
the generalisability to other populations, settings and situations include the:
l specifics of the hospital sites
l timing of approach for research
l interventional nature of the trials and studies
l parent experience of having an infant who survived and had participated in at least one study
l attitudes, behaviours and beliefs of the clinical and research teams involved.
Although we utilised purposive sampling, we did not record detailed demographic, socioeconomic or
educational information from the parents and did not explore how those factors, or other factors such
as ethnicity or religion, affect decision-making. Around half of our interviewees were parents of twins
or triplets, yet we do not explore in this report how that may affect decision-making. This may be
important, as recent studies suggest that such parents have important views on the co-randomisation
of their infants.88 In addition, we did not seek the views of parents who had declined participation in all
of the studies or trials that they had been offered or the feelings of parents whose infants had enrolled
in a study or trial but had subsequently died. The recent BRACELET study89 explored some of these
issues for parents when bereavement occurs in the context of RCTs in neonatal and paediatric
intensive care.
Our study supports existing data that suggest that parents make separate decisions about each
individual trial, judging each by its own perceived ‘pros and cons’.75,90 Our findings emphasise that
parents want to make final decisions about their infant’s participation and contrast with earlier data
that suggested that some parents wanted or expected health-care professionals to make the final
decision.71,91 Although most parents felt that they made good decisions that they did not later regret,
some parents suggested that they had not fully taken in or understood the trial information at the
time that they were approached and, as a result, some subsequent trial procedures came as a surprise.
This highlights the challenges of gaining fully informed consent and the importance of continued and
regular involvement of the research team to explain the nature and conduct of the study to parents,
as well as the rights of parents to withdraw or to decline specific procedures.71,74,75,82,91 Importantly,
however, most parents acknowledged that despite feeling stressed, they were still happy with their
decision to participate, frequently citing their faith in health-care professionals to protect their infant
from harm. Many parents in our study suggested that they would have liked information about the
trials and studies that were available before their infant was born and although many acknowledged
that there were time restraints on decision-making, they did not perceive these decisions to have been
made in haste or inadvisably either at the time or with hindsight.
Conclusions including implications for health care and recommendations for
additional research
This in-depth exploration of parents’ views on enrolling their infants into more than one RCT or study
highlights the need for research teams to be aware of a range of factors when approaching parents on
the NICU, especially in the context of co-enrolment. Although parents felt that they had made good
decisions and had few regrets, our study highlights that for some this may have been motivated by
guilt, a debt of gratitude or a lack of confidence to refuse. However, although parents acknowledged
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that fully informed consent was not possible, they were still happy that their decisions were ‘good
enough’ given the situation they were in. A deeper awareness of these factors would potentially enable
health-care professionals to support parents more fully throughout the process of enrolling their
infants on multiple trials.
The themes identified here could been used as part of training in good clinical practice and as part of
ongoing education for researchers, students, nurses, doctors and allied health professionals who are, or
may in the future be, involved in designing or supporting research. The study also suggests that careful
consideration is needed when PILs are developed and emphasises the importance of involving patients,
parents and/or members of the public in all aspects of research design. Modifications to the PIL may
be appropriate where co-enrolment is likely. The study also highlights the confusing and ‘overwhelming’
nature of having a sick infant who requires intensive care and the additional confusion when parents
are approached to join research studies. Providing such parents with additional opportunities to further
discuss and learn about the research objectives and procedures after they have consented and eliciting
their continued assent for their infants’ participation in the study will enhance their satisfaction and
understanding of the need for research that aims to improve patient care. Future research could assess
these modifications to see if they improve patient satisfaction and experience.
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Chapter 6 Evaluation of the effectiveness of
an incentive strategy on the response rate
in parents of preterm infants: a randomised
controlled study within a trial nested within SIFT
Background
Loss to follow-up has a detrimental effect on research studies. It can compromise internal and external
validity of results for a number of reasons. These include reduction of statistical power owing to
smaller sample size, negative impact on generalisability and potential to bias results.92 Therefore, it is
important to implement strategies to effectively maintain retention of participants.
Organising clinical assessments for follow-up can often be very costly in perinatal trials, so research
questionnaires are often used to capture follow-up data, including the primary outcome. Therefore, the
need to mitigate the loss to follow-up and maximise the return rate of questionnaires is essential.
Systematic reviews suggest that incentives are effective at improving response rates for research
questionnaires in clinical trials.93,94 Brueton et al.93 and Khadjesari et al.95 both reported that offering a
monetary incentive improved questionnaire return rates compared with no incentive, in both postal
and online settings. Edwards et al.94 reported that unconditional incentives (i.e. a reward given in
advance as a goodwill gesture) led to superior response rates compared with conditional incentives
(i.e. the promise of a reward on receipt of a questionnaire). However, there was significant heterogeneity
among these results (p < 0.00001). Dillman96 and Singer et al.97 also reported results that favoured
unconditional over conditional incentives.
However, use of financial incentives is costly and studies may not have the funds or resources available
to provide unconditional incentives. A conditional incentive, promised on receipt of a completed
questionnaire, could be a more cost-effective means of enhancing retention. Both direct costs and
resource costs could be reduced by rewarding only those participants who respond. It would minimise
wastage created by the monetary incentives sent out to non-responding participants. In studies of
incentive versus no incentive, similar gains are reported for both conditional and unconditional
incentives. Khadjesari et al.95 reported an increase of 9% when using a conditional incentive, whereas
Dillman96 described increases of 7–14% in studies using unconditional incentives. Furthermore,
Brueton et al.93 reported two studies (297 participants) that suggested that unconditional monetary
incentives provided no greater effect than conditional incentives (entry into a prize draw).
There is also a lack of evidence for the most effective incentive methods in the context of perinatal
RCT follow-up. There is sensitivity around the population (parents of vulnerable infants) and often a
lengthy time period between recruitment and longer-term outcomes that are captured at follow-up
(in this case 2 years). Hardy et al.98 successfully carried out a study of incentives at 1-year follow-up and
reported it to be the only known study of incentives in this population. Kenyon et al.99 investigated the
effects of incentives in a perinatal trial; however, this was for follow-up when the children were aged
7 years. It is, therefore, prudent to use the available opportunities to narrow the evidence gap as to
what works best.100 Given the significant heterogeneity in results in previous trials94 and the potential
serious effects of loss to follow-up, the need is still present to investigate which method of incentive
provides the greatest return, particularly in perinatal RCTs.
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The main objective of the SIFT study within a trial (SWAT) was to establish in the parents of preterm
infants whether offering an unconditional incentive in advance (with the first mailing of a questionnaire)
or promising an incentive (in the first mailing) on completion of a 2-year follow-up postal questionnaire
(conditional) improves the response rate. This randomised controlled SWATwas nested within the SIFT:
a multicentre RCT carried out in neonatal units in the UK and Republic of Ireland caring for very preterm
or VLBW infants. The primary outcome of the SIFT was survival without moderate or severe disability
at 24 months of age (CGA). This primary outcome was assessed by a questionnaire sent directly to
parents (principally to infants’ mothers). Questionnaires were sent both by post and by a link to an
online submission form via e-mail and SMS (short message service) message where these contact details
were available. The SWAT investigated whether or not an unconditional incentive (a monetary voucher
given before completion of a questionnaire) was more effective than a conditional incentive (the promise
of a monetary voucher on receipt of a completed questionnaire).
Changes to the SIFT protocol
The SIFT protocol was amended in 2015 to account for the use of financial incentives. The amendment
was approved by the NRES Committee and implemented in 2016. Funding was used from surplus
funding for direct research nurse funds on the trial, as recruitment finished 11 months early.
Consent
No additional consent from parents was sought for this SWAT. The PIL and original consent process
clearly indicated that the trial primary outcome was to be ascertained by a questionnaire at 24 months
of age CGA.
Sample size
Recruitment for the SIFT was completed on 30 June 2015, with 2804 infants randomised. Given that
there was an expected overall mortality rate of 5% for the population, it was estimated that 1250 of
these infants would survive to the projected start date of the study (originally 1 December 2016) and
that about 10% of the parents of these infants would be excluded from the follow-up owing to
withdrawal or to a lack of information on contact details or survival status. This would result in
approximately 1100 infants eligible for the SWAT, giving 550 infants per group.
It was estimated that the response rate with no incentives would be approximately 66%, based on past
experience from the BOOST-II UK trial,101 which had a similar patient population and 2-year follow-up
method.
Based on the most applicable studies that investigated incentives, it was anticipated that the addition
of an incentive would result in an absolute increase of 10% in the response rate.95,99 In total, 550
infants per group would allow detection of an absolute difference in response rate of around 7% at
90% power and a two-sided 5% level of significance.
Methods
Eligible participants were those who were recruited to the SIFT who were due to be sent a
questionnaire at the age of 24 months (CGA). Participants were recruited to SIFT in 55 recruiting
centres in the UK and the Republic of Ireland. Eligibility criteria for inclusion in SIFT have been
described elsewhere.1 Participants were traced to confirm survival and current residence. Where these
details could not be ascertained, parents were not contacted. In addition, parents who had withdrawn
consent to the 2-year follow-up were excluded.
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Participants were allocated randomly to one of two groups:
1. After group – the first paper letter to parents would include a promise of an incentive (£15 gift
voucher redeemable at high-street shops) after receipt of a completed form.
2. Before group – the first paper letter to parents would enclose the incentive (£15 gift voucher
redeemable at high-street shops) before the receipt of a completed form.
Participants were randomised in a 1 : 1 allocation ratio by permuted block randomisation (using
variable block sizes) and stratified by original SIFT allocation (faster feed increment/slower feed
increment) and by singleton/multiple birth. Infants from multiple births were allocated to the same
incentive group. Vouchers were allocated per questionnaire, so parents of multiple births received a
voucher for each infant.
The SIFT office staff at the NPEU CTU were aware of participant allocation owing to the nature of the
interventions and the practicalities involved in sending out the letters and the vouchers.
The incentive was a high-street shop voucher valued at £15 (€15 for participants recruited in the Republic
of Ireland), which was sent via post. Reminder letters in both groups mentioned the incentives. Letters to
those allocated to the after group reiterated the promise of an incentive. Letters to those allocated to
the before group tactfully mentioned the incentive that was sent with the first letter. Parents were also
contacted via text and/or e-mail to give reminders during the follow-up, although these contacts were not
included as part of the analysis of the number of reminders sent. All of the parents were provided with an
option of completing the questionnaire online or, as a last resort, via the telephone.
The incentives SWAT was implemented midway through the SIFT follow-up. All SIFT participants who
had returned their follow-up questionnaire prior to the incentives study being implemented were sent
a £15 voucher out of courtesy to ensure that there was fairness.
Outcomes
The primary outcome was the rate of questionnaire return, defined as receipt of a completed or
partially completed questionnaire at the SIFT office. A questionnaire was considered completed or
partially completed if the first three out of the five subsections of the questionnaire were completed
(as these sections were applicable to the derivation of the primary outcome for the main SIFT).
The secondary outcomes included the:
l primary method of completion (paper, online or telephone)
l total cost
l number of reminders.
The total cost included the postage, receipt of material via prepaid Freepost, cost of envelopes,
supplementary materials (e.g. sticker sets sent with questionnaires for infants to play with) and value of gift
vouchers. It did not include Freepost licence fee, printing, telephone calls and trial staff time. All costs for
participants were calculated in GBP. The cost of the €15 vouchers that were sent to the participants in the
Republic of Ireland was converted to GBP using the exchange rate (via xe.com) on 10 May 2017: the date of
the invoice for these vouchers. Costs for these participants also included the higher air mail postage fees.
Statistical analysis
The baseline demographic information was summarised by randomised group using frequency counts
and percentages for categorical data, means and SDs for normally distributed continuous data or
medians with IQRs for other continuous data.
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The comparative analysis entailed calculating the absolute difference in the proportion responding with
the corresponding 95% CI and the difference in mean cost (plus 95% CI). In addition, the cost in GBP
per 1% increase in response rate was calculated factoring in administration costs such as the number
of reminder letters, as well as the monetary value of the incentive. For other outcomes relating to the
method of completion and the reminder letters, a similar strategy was used based on the distributions/
type of data collected.
The principal comparison was the incentivised before group versus the incentivised after group.
The prespecified subgroup analysis examined the consistency of effect of the timing of the incentive
for SIFT original allocation (slower feed increment vs. faster feed increment) and singleton versus
multiple births using the statistical test of interaction.
The prespecified exploratory analysis examined the response rate in the period prior to the incentives
study starting, during the incentives study and overall (i.e. irrespective of incentive group allocation)
with a 95% CI. In addition, an analysis exploring ‘regional’ variation was performed.
No adjustment was planned for multiple testing as this SWAT involves a very small number of focused
hypothesis tests.
Results
Participant flow and baseline characteristics
In total, 923 infants were randomised to the SWAT (799 women). A total of 459 infants were allocated
to receive the incentive before completion. Out of these, three were not sent questionnaires because
addresses and survival status could not be confirmed. A total of 464 infants were allocated to receive
the incentive after completion. Out of these, 11 were not sent questionnaires because addresses and
survival status could not be confirmed and two of the infants were randomised in error. In these two
cases, both were later found to have died after they were randomised to the SWAT. All 923 infants
were included in analysis (Figure 7). Baseline comparability was balanced across the infant and
maternal characteristics at trial entry (Table 14).
Infants allocated to receive
incentive before the receipt
of a completed form
(before group)
(n = 459)
Infants included in analysis
(n = 459) 
Infants allocated to receive
incentive after the receipt
of a completed form
(after group)
(n = 464)   A
ll
o
ca
ti
o
n
A
n
a
ly
si
s Infants included in analysis
                     (n = 464) 
Two infants died following
randomisation to the
incentives studya
Infants randomised
(n = 923)
• Women, n = 799 
FIGURE 7 Flow of participants through the incentives SWAT. a, Included in the analysis where data are available.
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TABLE 14 Infant and maternal characteristics at trial entry
Characteristic Before group (N= 459) After group (N= 464)
Number of centres, n 51 51
Allocated to faster group in SIFT,a n/N (%) 226/459 (49.2) 231/464 (49.8)
Male sex, n/N (%) 229/459 (49.9) 257/463 (55.5)
Missing, n 0 1
Infant age at randomisation (days)
Median (IQR) 4 (3–6) 4 (3–6)
Birthweight of < 10th centile for gestational age, n/N (%) 106/459 (23.1) 77/463 (16.6)
Missing, n 0 1
Gestation at delivery (weeks)
Median (IQR) 29 (27–31) 29 (27–30)
23+0 to 23+6, n/N (%) 4/459 (0.9) 7/464 (1.5)
24+0 to 24+6, n/N (%) 21/459 (4.6) 26/464 (5.6)
25+0 to 25+6, n/N (%) 31/459 (6.8) 44/464 (9.5)
26+0 to 27+6, n/N (%) 101/459 (22.0) 107/464 (23.1)
28+0 to 29+6, n/N (%) 129/459 (28.1) 117/464 (25.2)
30+0 to 31+6, n/N (%) 146/459 (31.8) 145/464 (31.3)
32+0 to 36+6, n/N (%) 27/459 (5.9) 18/464 (3.9)
Birthweight (g)
Mean (SD) 1139.5 (331.8) 1131.8 (319.4)
< 500 g, n/N (%) 0/459 (0.0) 2/464 (0.4)
500 to 749 g, n/N (%) 59/459 (12.9) 57/464 (12.3)
750 to 999 g, n/N (%) 111/459 (24.2) 114/464 (24.6)
1000 to 1249 g, n/N (%) 124/459 (27.0) 114/464 (24.6)
1250 to 1499 g, n/N (%) 91/459 (19.8) 115/464 (24.8)
≥ 1500 g, n/N (%) 74/459 (16.1) 62/464 (13.4)
Infant heart rate > 100 b.p.m. at 5 minutes, n/N (%) 421/455 (92.5) 418/456 (91.7)
Missing, n 4 8
Infant temperature on admission (°C)
Mean (SD) 36.8 (0.7) 36.8 (0.8)
Missing, n 4 2
Infant worst base excess within the first 24 hours after birth (mEq/l)
Mean (SD) –6.0 (3.9) –6.1 (4.1)
Missing, n 8 10
Infant ventilated via endotracheal tube at randomisation, n/N (%) 90/458 (19.7) 107/463 (23.1)
Missing, n 1 1
Infant had absent or reversed end diastolic flow, n/N (%) 76/452 (16.8) 70/455 (15.4)
Missing, n 7 9
continued
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Primary outcome
In total, 381 infants allocated to the before group had a questionnaire returned (out of 459, 83.0%)
compared with 353 infants allocated to the after group (out of 464, 76.1%) (Table 15). An unconditional
£15 incentive upfront (before group) led to a statistically significantly higher response rate than a
conditional incentive (after group), with an absolute difference of 6.8% (95% CI 1.6% to 12.0%;
p = 0.01), adjusted for stratification factors (trial allocation and single or multiple birth).
Secondary outcomes
Method of completion
In total, 326 questionnaires were completed (and returned) on paper in the before group (out of 459,
71.0%) compared with 295 questionnaires in the after group (out of 464, 63.6%) (see Table 15).
Completion rates online were broadly similar between groups, with 50 questionnaires (out of 459,
10.9%) returned in the before group and 53 questionnaires (out of 464, 11.4%) returned in the after
group. Five questionnaires were completed over the telephone in each group (1.1%). The difference in
response rates appears to be dominated by paper completion.
Cost
The mean cost of the incentive strategy per infant was £17.97 (SD £1.7) in the before group and
£15.00 (SD £6.7) in the after group (see Table 15). The mean cost of the unconditional incentive
scheme was £21.65 per response compared with £19.72 per response for the conditional incentive.
The mean cost per 1% increase in response is £1.35 per infant in the before group compared with
£2.95 per infant in the after group.
TABLE 14 Infant and maternal characteristics at trial entry (continued )
Characteristic Before group (N= 459) After group (N= 464)
Mother’s age at randomisation (years)
Mean (SD) 30.7 (5.8) 31.2 (6.5)
Multiple pregnancy,a,b n/N (%) 144/459 (31.4) 139/464 (30.0)
Singles,c n 0 1
Twins,d n 136 116
Triplets,e n 8 22
Caesarean section delivery, n/N (%) 284/459 (61.9) 272/464 (58.6)
Membranes ruptured before labour, n/N (%) 167/453 (36.9) 159/460 (34.6)
Missing, n 6 4
Membranes ruptured > 24 hours before delivery, n/N (%) 119/454 (26.2) 104/458 (22.7)
Missing, n 5 6
b.p.m., beats per minute.
a Minimisation factor.
b Sometimes only one infant from a multiple pregnancy met the inclusion criteria and was recruited.
c The number of infants from multiple pregnancies where the other fetuses were aborted, miscarried or stillborn.
d The number of infants who were one of twins.
e The number of infants who were one of triplets.
Unless otherwise stated the table gives the percentages of infants with data in that group of the trial who had
(or whose mother had) the stated characteristic.
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TABLE 15 Primary and secondary outcomes in the SWAT
Outcome Before group (N= 459) After group (N= 464)
Unadjusted effect
measure (95% CI)a p-value
Adjusted effect
measure (95% CI)a,b p-value
Questionnaire received (at 24 months
of age CGA),c n/N (%)
381/459 (83.0) 353/464 (76.1) 6.9 (1.7 to 12.1) 0.009 6.8 (1.6 to 12.0) 0.010
Method of completion, n/N (%)
Paper questionnaire 326/459 (71.0) 295/464 (63.6) 0.061d
Online completion 50/459 (10.9) 53/464 (11.4)
Completion via telephone 5/459 (1.1) 5/464 (1.1)
Total cost of the strategye (£)
Mean (SD) 17.97 (1.7) 15.00 (6.7) 2.97 (2.33 to 3.60) < 0.001 2.98 (2.34 to 3.61) < 0.001
Median (IQR) 18.22 (17.41–18.40) 18.08 (18.08–18.88)
Increase in cost compared with prior
to commencement of incentives study
(95% CI)
14.80 (14.68 to 14.94) 11.84 (11.51 to 12.12)
Reminders required,f n/N (%) 248/456 (54.4) 264/452 (58.4)
0 208/456 (45.6) 188/452 (41.6)
1 104/456 (22.8) 95/452 (21.0) 0.027
g
2 43/456 (9.4) 31/452 (6.9)
3 101/456 (22.1) 138/452 (30.5)
Missing, n 3 12
a Absolute difference in the proportion responding and mean difference for cost.
b Adjusted for stratification factors: trial allocation and single or multiple birth.
c Receipt of a completed or partially completed (defined as completion of the first three sections or more) questionnaire at the SIFT office (note that the denominator is the number
of eligible infants, which takes into account multiple births).
d p-value for chi-squared test.
e Costs included postage, receipt of material via Freepost, envelopes, sticker sets and value of gift vouchers but excluded costs of Freepost license fee, printing, telephone calls and
trial staff time.
f Reminder 1 sent by post, reminder 2 sent by post plus accompanying telephone call and reminder 3 was by telephone call only.
g p-value for chi-squared test for trend (linear association).
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The additional cost of the incentives strategies per infant compared with prior to the incentives
study was £14.80 for the before group and £11.84 for the after group. Unsurprisingly, providing the
incentive upfront was more costly; however, the mean difference in the cost per infant was only £2.99
(95% CI £2.33 to £3.61).
Number of reminders
There was evidence to suggest that fewer reminders were required in the before group (54.4%) than in
the after group (58.4%) (Table 16). Furthermore, a higher proportion reached the third (final) reminder
stage in the after group (138/452, 30.5%) than in the before group (101/456, 22.1%).
Prespecified subgroup analysis
There was no evidence of a differential effect of the incentives strategy between the original SIFT
allocations (faster feed increment/slower feed increment) or between single and multiple births.
However, the response rate from parents of multiples was higher in the before group than the after
group (see Table 16 and Figure 8), but the test of interaction is not statistically significant and the
finding may be, in part, simply due to the increased amount (double or triple) received unconditionally.
TABLE 16 Subgroup analyses for response rate at 24 months of age
Questionnaire
received
Before group
(N= 459)
After group
(N= 464)
Unadjusted risk
difference (95% CI) p-valuea
Adjusted risk
difference (95% CI)b p-valuea
Trial allocation,
n/N (%)
0.530 0.529
Faster feed
increment
188/226 (83.2) 180/231 (77.9) 5.3 (–2.0 to 12.5) 5.2 (–2.0 to 12.5)
Slower feed
increment
193/233 (82.8) 173/233 (74.2) 8.6 (1.2 to 16.0) 8.5 (1.1 to 16.0)
Multiple birth,
n/N (%)
0.102 0.102
Singleton 258/315 (81.9) 253/325 (77.8) 4.1 (–2.1 to 10.3) 4.0 (–2.2 to 10.2)
Multiple 123/144 (85.4) 100/139 (71.9) 13.5 (4.0 to 22.9) 13.4 (4.0 to 22.8)
a p-value for test for interaction.
b Adjusted for other stratification factor, trial allocation and multiple birth.
Subgroup
Trial arm
Faster feed increment
Slower feed increment
Multiple birth
Singleton
Multiple
258/315
123/144
188/226
193/233
180/231
173/233
253/325
100/139
Before (n/N) After (n/N)
Risk difference
(95% CI) p-value
0.529
0.102
–20 0 20 40
After better Before better
5.2 (–2.0 to 12.5)
8.5 (1.1 to 16.0)
4.0 (–2.2 to 10.2)
13.4 (4.0 to 22.8)
FIGURE 8 Subgroup analyses for response rate at 2 years.
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Prespecified exploratory analysis
We examined the response rate prior to and during the incentives study and overall (i.e. irrespective of
allocation) (Table 17). Again, not surprisingly, the response rate following the implementation of the
vouchers was statistically significantly higher (79.5%, 95% CI 76.8% to 82.0%) than before the
implementation of the vouchers (72.1%, 95% CI 69.9% to 74.1%).
In addition, we examined the response rate in terms of regional variation during the incentives study
(Table 18). Unfortunately, the vast majority of the infants were randomised in England and so these
results were difficult to interpret. In the Republic of Ireland the trend is reversed, whereas in Scotland
response rates were lower in both groups.
Discussion
In this SWAT, an unconditional incentive (before group) produced a significantly more favourable
response rate than a conditional incentive (after group), with an absolute increase of 6.8% (83.0% vs.
76.1%, respectively). This mirrors results from previous studies.94,97 The overall response rate was
significantly higher after the SWAT was implemented (79.5%, 95% CI 76.8% to 82.0%) than before it
was implemented (72.1%, 95% CI 69.9% to 74.1%).
The majority of questionnaires were returned by post and this method saw the significant increase
between groups. There was little difference between groups for the online or telephone-supplied
questionnaires but there were relatively small numbers of responses overall via these two methods.
TABLE 18 Examining any regional effects on response rate at 24 months of age
Questionnaire
received
Before group
(N= 459)
After group
(N= 464)
Unadjusted risk
difference (95% CI) p-valuea
Adjusted risk
difference (95% CI)b p-valuea
Region,
n/N (%)
0.636 0.640
England 308/367 (83.9) 295/381 (77.4) 6.5 (0.9 to 12.1) 6.5 (0.9 to 12.2)
Scotland 37/48 (77.1) 26/43 (60.5) 16.6 (–2.2 to 35.5) 16.6 (–2.2 to 35.5)
Wales 14/16 (87.5) 10/13 (76.9) 10.6 (–17.5 to 38.6) 10.6 (–17.5 to 38.6)
Northern
Ireland
11/13 (84.6) 11/14 (78.6) 6.0 (–23.1 to 35.1) 6.1 (–23.1 to 35.2)
Republic of
Ireland
11/15 (73.3) 11/13 (84.6) –11.3 (–41.0 to 18.5) –11.2 (–41.1 to 18.6)
a p-value for test for interaction.
b Adjusted for stratification factors trial allocation and single or multiple birth, where technically possible.
TABLE 17 Response rate at 24 months of age prior to and during the incentives study
Questionnaire received
Prior to the incentives study (N= 1756) During the incentives study (N= 923)
n/N (%) 95% CI n/N (%) 95% CI
Questionnaire received
(at 24 months of age
CGA)
1266/1756 (72.1) 72.1 (69.9 to 74.1) 734/923 (79.5) 79.5 (76.8 to 82.0)
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Both of the incentive methods are cost-effective in terms of increasing response rate. However,
providing an unconditional incentive comes with an additional cost, in this case almost £3 per infant.
The before group led to an absolute increase in response rate of 11%, at an average additional cost of
£14.80 per infant. The after group led to an absolute increase in response rate of 4%, at an average
additional cost of £11.84 per infant. Therefore, although the unconditional incentive is more expensive,
it represents good value for money with a cost of £1.35 per infant for every 1% increase in response
rate. This is in contrast to the conditional incentive that costs an additional £2.95 per infant for every
1% increase in response rate.
There was no evidence of a differential response rate between trial allocations or between single and
multiple births; however, there was a greater response from parents of multiples in the before group.
We could postulate that there is a cumulative factor involved here, as parents of multiples received
greater upfront incentives (£30 for twins, £45 for triplets) than parents of singletons (£15 for one
infant). Previous systematic reviews have reported that higher incentive amounts lead to higher
response rates.93
Strengths and limitations
This SWAT, nested within a perinatal RCT, contributes to the evidence base for methods of incentive
in this context. This study was run efficiently and required minimal resource, as it was added to the
existing SIFT study and was run without additional staff time. Delays in ethics approval and logistical
management meant that the SWAT study did not begin until February 2017, which resulted in fewer
infants due to receive their questionnaire and thus participate. Despite this, results showed a significant
increase in the response rate in the group allocated an unconditional incentive (before group).
This study is limited to a particular study population: parents of infants born prematurely. It is also
limited to the follow-up period of 2 years. Given the scarcity of studies in the context of perinatal
RCTs, it is important to bear this in mind. Longer follow-up periods (e.g. at school age), different modes
of data collection and assessment (e.g. clinical assessment) and other incentive amounts may produce
different results.
Implications
This SWAT provides strong evidence that incentives can be a cost-effective strategy to maximise
follow-up in perinatal RCTs. It also demonstrates that giving the incentive voucher before receiving
the questionnaire is more effective than giving the incentive voucher after. Indeed, an unconditional
incentive strategy, although more expensive than a conditional incentive strategy, pays dividends with a
significantly higher response rate. This SWAT gives a clear indication of the potential benefit, which
may be helpful to other triallists considering the same approach.
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Chapter 7 Discussion and conclusions
Summary of main findings
The SIFT shows that advancing enteral feed volumes at daily increments of 18 ml/kg versus 30 ml/kg
does not affect survival without moderate or severe neurodevelopmental disability at 24 months CGA
or affect the risks of LOS or NEC in very preterm or VLBW infants. Advancing feeds more quickly
reduced the duration of parenteral nutrition by 2 days but was associated with an unexpected increase
in the frequency of abnormal motor outcomes at 24 months CGA.
To our knowledge, the SIFT is the first study to assess the neurodevelopmental outcome in relation to
the speed of increasing feeds. Although the composite primary outcome was not statistically different
between the two groups, the unexpected finding of an observed increase in the risk of moderate or
severe motor impairment in the faster feed increment group requires consideration. This makes it
unclear which increment to adopt in clinical practice and was notable as we anticipated that those
infants in the faster increment group would have better outcomes at 24 months CGA than those
infants in the slower group, unless there was an increased risk of NEC that was not outweighed by a
reduction in LOS for faster-fed infants. The result is more perplexing in that there were numerically
fewer cases of LOS and NEC in the faster group. It is possible that this is a chance finding, but there
are biologically plausible mechanisms that could explain it, such as increased cardiorespiratory events
as a result of pressure on the diaphragm,102 impaired cerebral blood flow autoregulation103 or the
inability to digest and absorb enteral nutrition.104–107
The quality and power of the trial enhances the validity of the findings. Practices were used to limit
bias, including central web-based randomisation for allocation concealment. We obtained a high rate
of follow-up and assessed the trial cohort with intention-to-treat analyses based on a prespecified
statistical analysis plan. The trial achieved recruitment of 2804 participants, as per protocol based on
the a priori sample size estimation. This sample was inflated before the trial commenced to allow for
correlation in the primary outcome between twins and multiple siblings who received the same
intervention as their siblings. This approach was taken after consulting parents of multiple birth siblings
and representative groups who raised concerns about feeding siblings at different rates.
At randomisation, demographic and prognostic characteristics were well balanced between the two
groups, with a minimisation algorithm ensuring that there was balance for major known or anticipated
prognostic indicators (i.e. hospital, multiple birth, gestational age ranges and birthweight of < 10th centile
for gestational age) or potential confounding influences, such as recruiting site. Interim analyses by the
trial’s independent DMC used strict criteria to minimise the chances of spurious findings due to data
fluctuations before a sufficient sample size was achieved. Adherence to the allocated interventions was
high, the incidence of protocol violations was low and primary outcome data were available for 89.8% of
the trial cohort.
The PARCA-R is a parent-completed assessment of cognitive and language development at 24 months
of age.37 It has good concurrent validity and test–retest reliability and, using published cut-off scores
for identifying preterm children at risk of developmental delay, it has excellent diagnostic utility
(sensitivity and specificity of > 80%) for identifying those with moderate to severe delay, as determined
by scores of < –2 SD on a gold-standard developmental test.37 It is widely used both as an assessment
in routine developmental follow-up (e.g. as recommended for use in neonatal follow-up in the NICE
guideline108 for ‘developmental follow-up of children and young people born preterm’ in the UK) and as
an outcome measure in observational studies and clinical trials.37 The resources that are required to
carry out gold-standard tests prohibit their use in large-scale studies, especially where there are large
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geographically dispersed cohorts as in SIFT. Thus, the PARCA-R provides a cost-efficient alternative
to examiner-administered tests for assessing cognitive and language outcomes at 24 months of age.
However, like many developmental screening tools, lower positive predictive values (PPVs) may result
in over-referrals or false positives. In studies comparing the PARCA-R with a gold-standard test, PPVs
have ranged from 23% to 65% in samples of children born preterm. As such, a higher rate of positive
screens is found on the PARCA-R than the rate of children identified by an examiner using a
standardised test.37,109,110 Therefore, the proportion of children with moderate to severe developmental
delay as measured by scores of < –2 SD is likely to be lower than observed in SIFT. However, studies
have shown that preterm children with false-positive responses represent a high-risk group and have
significantly poorer developmental outcomes than those with true-negative screens and, thus, have a
higher risk of long-term intellectual disability.37,110,111
Maximising developmental follow-up and minimising participant attrition is a key concern for researchers,
given that selective loss to follow-up can bias results.111,112 In the UK this is increasingly challenging and
completion rates for questionnaire-based follow-up have recently been reported at approximately
≤ 60%.44,113,114 Intensive efforts were therefore made to maximise response rates at 24 months of age
CGA in SIFT, as detailed in Appendix 10, which shows the return rate of questionnaires alongside the
timings of the interventions. The 72% response rate of completed, classifiable, SIFTquestionnaires, with
the addition of classifications of outcomes obtained from blinded end-point review of routine clinical
follow-up data (11.2%), meant that we achieved an excellent overall follow-up rate of 83.2%, where a
classification of disability was possible in survivors at 24 months of age.
Event rates for the primary and secondary outcomes were different from those we anticipated when
estimating the sample size required for the trial.2,33 There were fewer deaths than expected, which was
probably a result of the timing of randomisation that took place in a median of 4 days of age for both
groups, by which time most neonatal deaths have already occurred.115 The rates of LOS and NEC were
similar to previous studies; however, NEC occurred in 5.3% of SIFT participants compared with 6.95%
of participants in previous studies and invasive (confirmed) infection was seen in 18.4% versus
18.8%, respectively.13
To our knowledge, almost three times as many infants participated in SIFT than in all of the existing
trials combined; this suggests that we were able to produce more precise estimates of effect size than
those available before SIFT. Analysis of secondary outcomes demonstrated that the number of days
to reach full milk feeds and the number of days of parenteral nutrition were reduced with faster
increments. Although the 95% CI for the relative risk estimate for the primary outcome was not
statistically significant, it excludes a > 1% reduction in risk and a ≥ 18% increase in risk for those fed
at 30 ml/kg/day compared with those fed at 18 ml/kg/day.
These results substantially outweigh data from previous trials,24–32 as large numbers of high-risk infants
were recruited, including 1020 extremely low-birthweight infants, 994 extremely preterm infants and
435 infants with absent or reversed end diastolic flow in the umbilical artery on antenatal Doppler
studies.
Limitations
A limitation of the trial is that is was not blinded, as it would have been difficult to safely and
completely blind caregivers and parents to the feed rate. This is unlikely to have influenced the
ascertainment of the most important outcomes, which were reviewed by BERCs. It is possible that
knowledge of allocation could alter clinician practice, for example stopping feeds more often or
diagnosing suspected NEC in faster increment infants. We did, however, see fewer cases of NEC in
the faster increment group, suggesting that this did not occur often.
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Infants were a median age of 4 days at commencement of the intervention and some clinicians may
have been less likely to enrol the highest-risk infants. The trial does not, therefore, allow conclusion
about the safety of different feed advancement increments in the first few days after birth.
Subgroup analyses
The subgroup analyses were informative, as they did not show significant findings but, as with all such
analyses, they are inherently underpowered. The one statistically significant finding in the subgroup
analysis was evidence of excess adverse outcome in the small number of faster increment infants
(18/30) who received formula milk alone compared with slower increment infants (12/40). Higher-risk
infants (including those with abnormal Dopplers) did not do worse with faster feed increments (see
Figures 3 and 4 and Table 4). As the size of the group that received formula alone comprised 93 infants
only, with 24-month outcomes not being known in 23 infants and including 16 infants in the faster
increment group, it is likely that survival without moderate or severe disability being lower in the faster
group is a chance finding. Further analysis is planned given that 1666 infants received a mix of breast and
formula milk. It is possible that a higher proportion or volume of breast milk could protect against a poor
outcome through anti-infective or anti-inflammatory mechanisms. It was a limitation of the study that
additional granularity was not used in this subgroup analysis.
In post hoc analyses, we did not show any evidence that absent or reversed end diastolic flow that
was detected by antenatal Dopplers of the umbilical arteries increased the risk of NEC with the faster
feed increment.
Cost analyses
Given the apparently worse motor outcome at 24 months CGA, increasing the milk feed volumes at a
faster rate in very preterm or VLBW infants is not a cost-effective strategy. Although it may reduce
the burden on scarce health-care resources in the short term, the cost–consequences of this strategy
in the long term are likely to be too severe to recommend this clinical practice.
Qualitative analysis of parent views
This in-depth exploration of parents’ views on enrolling their infants into more than one RCT or study
highlights the need for research teams to be aware of a range of factors when approaching parents
about multiple studies on the NICU. Although parents felt that they had made good decisions and had
few regrets, our study highlights that, for some, this may be motivated by guilt, a debt of gratitude or a
lack of confidence to refuse. A deeper awareness of these factors would enable health-care professionals
to support parents more fully through the process of enrolling their infants on multiple trials.
The study also suggests that careful consideration is needed when PILs are developed and emphasises
the importance of involving patients, parents and/or members of the public in all aspects of research
design. The study also highlights the confusing and ‘overwhelming’ nature of having a sick infant
requiring intensive care and the additional confusion when they are approached to join research
studies. Providing such parents with additional opportunities to further discuss and learn about the
research objectives and procedures after they have consented and eliciting their continued assent for
their infants’ participation in the study may be important mitigation.
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Incentives trial
The incentives study was an important part of increasing the follow-up rate in the trial to ensure that the
primary outcome was known in > 90% of cases after other data sources were also taken into account.
The unconditional incentive given before receiving the questionnaire produced a more favourable response
rate than a conditional incentive, with an absolute increase of 6.8% (83.0% vs. 76.1%, respectively). The
overall response rate was significantly higher after the SWATwas implemented (79.5%, 95% CI 76.8% to
82.0%) than before it was implemented (72.1%, 95% CI 69.9% to 74.1%), suggesting that both methods
of incentives can be an effective strategy in maximising return rates.
Applicability
The SIFT findings are likely to be applicable both in the UK and internationally. Participants were
enrolled in 55 neonatal units across the UK and in the Republic of Ireland, which gave a broad
geographical, social and ethnic representation. Many infants who were enrolled in a recruiting site
were subsequently transferred to another neonatal unit of ongoing care, usually closer to home. Trial
participation continued in another 78 neonatal units, which mirrored care pathways for preterm infants
in managed clinical networks in the UK.
The trial population was representative of very preterm or VLBW infants who were cared for within
health-care facilities in well-resourced health services and included a substantial proportion of
extremely preterm infants (36%) and of infants with other putative risk factors for neonatal morbidity,
such as prolonged rupture of maternal amniotic membranes (24%) and evidence of absent or reversed
end diastolic flow in the umbilical artery (16%). Overall, 30.4% of participants acquired a microbiologically
confirmed or clinically suspected late-onset infection and, in total, 18.4% had a microbiologically confirmed
infection, which was consistent with rates reported from cohort studies and other RCTs.18–20,22,24–32
Similarly, the incidence of NEC (5.3%) was similar to rates reported in large, population-based
surveillance and cohort studies and RCTs.72
Implications for practice
The SIFT does not conclusively support the routine use of faster or slower enteral feed increments at
daily increments of 18 ml/kg versus 30 ml/kg. Neither rate affected the primary outcome of survival
without moderate or severe neurodevelopmental disability at 24 months of age or the risk of LOS
or NEC in very preterm or VLBW infants. Advancing feeds more quickly reduced the duration of
parenteral nutrition use by 2 days but was associated with an unexpected increase in the frequency of
abnormal motor outcomes at 24 months CGA. Clinicians reviewing these data will need to weigh up
the relative importance of the secondary outcomes when deciding how fast to increase the milk feeds
of infants in their care.
Implications for research
Further randomised trials and examination of feeding data sets (either existing or prospectively
collected) may provide further information. Research efforts should continue to investigate the
aetiology, epidemiology and pathogenesis of complications from faster and slower feeding, with a
particular focus on neurodevelopmental outcomes in relation to milk-feeding practices. They should
also aim to develop, refine and assess feeding interventions that may prevent or reduce adverse
acute and long-term consequences for very preterm infants and their families. Assessing different
incremental feeding increments may be of benefit, as different groups of infants may respond
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differently to different increments (e.g. extremely premature infants). It may also be worthwhile to
assess different increments in other groups, as these increments may also be better for those exposed
to associated risk factors such as formula milk or placental dysfunction. Further detailed analysis of the
association between milk types and outcomes is planned using data from this trial. Interventions to improve
parental understanding, experience and acceptance of multiple research studies also warrant study.
Patient and public involvement
The SIFT was facilitated by close engagement with infant and family representatives experienced in
service-user representation. Bliss, the UK national charity for ‘babies born premature or sick’, and
parents of children who had received neonatal intensive care contributed to development of trial
materials (e.g. PILs and consent forms) and to training of research staff (e.g. in simulated ‘consent-
seeking’ sessions). This assistance was extremely beneficial and an important part of the successful
delivery of the study.
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Appendix 1 Recruiting neonatal units
Recruiting site Principal investigator Research staff
Altnagelvin Area Hospital, UK Damien Armstrong Julie Brown
Arrowe Park Hospital, Wirral, UK Srinivasarao Babarao/Adrian Hughes Sharon Hughes, Lucy Lewis and
Rachael Rice
Birmingham City Hospital, UK Fiona Chambers/Shanmugasundaram
Sivakumar
Lara Alamad, Rania M El Beltagy,
Lisa Charles and Sarah Potter
Birmingham Heartlands Hospital, UK Imogen Storey Francesca Bisso, Juliet Hopkins and
Lucy Ingram
Birmingham Women’s Hospital, UK Alison Bedford Russell/Gemma
Holder
Heather Barrow, Rachel E. Jackson
and Elizabeth Simcox
Bradford Royal Infirmary, UK Sunita Seal Liz Ingram, Rachel Wane and
Kelly Young
Calderdale Royal Hospital, UK Eilean Crosbie Salamiah Burgess, Amanda Smith and
Kristy Somerville
Countess of Chester Hospital, UK Stephen Brearey Caroline Burchett, Sarah de-Beger
and Yvonne Farmer
Craigavon Area Hospital, UK Philip Quinn/Michael Smith Sara Gilpin and Judith Ratcliffe
Croydon University Hospital, UK John Chang Aline Cook and Vana Wardley
Derbyshire Children’s Hospital, UK John McIntyre/Mal Ratnayaka Coral J Smith and Vanessa Unsworth
Derriford Hospital, UK Oladipo Aworinde/Nicola Maxwell Louise Meredith, Sarah-Jane Sharman
and Susan Tyson
Gloucestershire Royal Hospital, UK Miles H Wagstaff Susan Beames
Great Western Hospital, Swindon, UK Girish Gowda Rebecca Elliott-Jones
Hull Royal Infirmary, UK Hassan Gaili Gail Bartley, David Bolton and
Sarah Trufhitt
James Cook University Hospital,
Middlesbrough, UK
Mithilesh Lal Suzanne Bell, Mandy Forster and
Helena Smith
Jessop Wing, Sheffield, UK Robert Coombs Pauline Bayliss, Julie Cook and
Clare Pye
John Radcliffe Hospital, Oxford, UK Kenny McCormick Sheula Barlow and Sara Davis
Kettering General Hospital, UK Jasmina Marinova Harsha Bilolikar and Sonia White
King’s Mill Hospital, Sutton-in-
Ashfield, UK
Vibert Noble/Simon Rhodes Yvonne Lisseman-Stones,
Caroline Moulds and Karen Whysall
Leeds General Infirmary/St James’s
University Hospital, Leeds, UK
Kathryn Johnson Marjorie Allen, Deborah Burton,
Stephanie Heath, Suzanne Laing,
Charlotte Reilly, Collette Spencer
and Lindsay Uryn
Leicester Royal Infirmary, UK Elaine Boyle Rosalind Astles and Marie Hubbard
Leighton Hospital, Crewe, UK Arumugavelu Thirumurugan Sarah Bramhall, Sally A Smith and
Samantha Tapscott
National Maternity Hospital, Dublin,
Republic of Ireland
Anne Twomey Breda Coronella
New Cross Hospital,
Wolverhampton, UK
Babu Kumararatne/Alyson Skinner Rebecca Denyer and Sharon Kempson
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Recruiting site Principal investigator Research staff
Northampton General Hospital, UK Subodh Gupta/Fiona Thompson Hannah Graham
Nottingham City Hospital/
The Queen’s Medical Centre,
Nottingham, UK
Jon Dorling Dushyant Batra, Sarah Craig,
T’ng Chang Kwok, Julie Lynch,
Alison Paton, Jodie Sibert and
Rachel Smitheram
Pinderfields General Hospital,
Wakefield, UK
Kathryn Deakin Gail Castle and David Gibson
Princess Anne Hospital,
Southampton, UK
Mark J Johnson/Alison Leaf Philippa Crowley, Charlotte Oates,
Jenny Pond and Jane Rhodes
Princess Royal Maternity, Glasgow, UK Helen Mactier Isobel Crawford
Queen Alexandra Hospital,
Portsmouth, UK
Tim Scorrer Michelle Pople
Queen’s Hospital, Romford, UK Wilson Lopez/Khalid Mannan Helen Smith
Royal Berkshire Hospital, Reading, UK Nicola Pritchard Sue Hallett and Morag Zelisko
Royal Cornwall Hospital, Truro, UK Yadlapalli Kumar Barbara Bromage, Gillian Craig and
Hannah Osborn
Royal Devon and Exeter Hospital, UK David Bartle Julia Halpin, Nicola Jones,
Jackie Massey, Aileen Roberts,
Jacqui Tipper and Sue Ward
Royal Infirmary of Edinburgh, UK Ben Stenson Lynn Clark
Royal Maternity Hospital, Belfast, UK Stanley Craig Patricia McCreesh, Muriel Millar,
Mary O’Neill and Alison Walker
Royal Shrewsbury Hospital, UK Sanjeev Deshpande Sarah Kirk and Charlotte Owen
Royal Stoke University Hospital, UK Lee Abbott Anne Harrison, Julie Hollins,
Ruth Jones, Katharine Lewney,
Rachel Pringle, Viki Riches and
Eric Roe
Royal Victoria Infirmary, Newcastle, UK Janet Berrington/Nicholas Embleton Tracey Downes, Julie Groombridge,
Alison Kimber, Julie Pirnie, Lynda Shah,
Thomas Skeath, Linda Smith and
Stefan Zalewski
Singleton Hospital, Swansea, UK Sujoy Banerjee Amanda Cook, Helen Goldring and
Malini Ketty
Southern General Hospital,
Glasgow, UK
Colin Peters Lorna McKay
Southmead Hospital, Bristol, UK Paul Mannix Anne Gay and Diane Stubbs
St George’s University Hospitals
NHS Foundation Trust, London, UK
Nigel Kennea Naomi Hayward
St Michael’s Hospital, Bristol, UK Pamela Cairns/Jonathan Davis Joanne Innoles
St Peter’s Hospital, Chertsey, UK Peter Reynolds Nicola Holland and Karen Wells
Sunderland Royal Hospital, UK Majd Abu-Harb Donna Coppard, Kathryn Marshall
and Eileen Turnbull
United Lincolnshire Hospitals Trust, UK Narasimha Kollipara Susie Butler, Ruchika Gupta,
Amanda Roper and Dougie Thomas
University Hospital Coventry, UK Richard C de Boer Kathryn Blake and Geraldine Ward
University Hospital of North Tees, UK Sundaram Janakiraman Wendy Cheadle and Alex Ramshaw
Warrington Hospital, UK Satish Hulikere/Delyth Webb Natalie Rogers
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Recruiting site Principal investigator Research staff
William Harvey Hospital, Ashford, UK Vimal Vasu Shermi George, Jodie Harrison and
Stephanie O’Brien
Wishaw General Hospital, UK Samuel Ibhanesebhor Denise Vigni
Worcestershire Royal Hospital, UK Andrew Gallagher Dawn Kelly and Catherine Townsend
York Hospital, UK William McGuire/Guy Millman William McGuire and Anna Clayton
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Appendix 2 Continuing care sites
The continuing care sites were as follows:
l Airedale NHS Foundation Trust, Keighley, UK
l Alder Hey Children’s Hospital, Liverpool, UK
l Barnet Hospital, London, UK
l Basingstoke and North Hampshire Hospital, Basingstoke, UK
l Birmingham Children’s Hospital, Birmingham, UK
l Borders General Hospital, Melrose, UK
l Burnley General Hospital, Burnley, UK
l Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
l Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, UK
l Cumberland Infirmary, Carlisle, UK
l Darlington Memorial Hospital, Darlington, UK
l Diana, Princess of Wales Hospital, Grimsby, UK
l Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK
l Dorset County Hospital, Dorchester, UK
l Dumfries and Galloway Royal Infirmary, Dumfries, UK
l East Surrey Hospital, Redhill, UK
l Forth Valley Royal Hospital, Larbert, UK
l Frimley Park Hospital, Frimley, UK
l George Eliot Hospital, Nuneaton, UK
l Harrogate District Hospital, Harrogate, UK
l Hereford County Hospital, Hereford, UK
l Homerton Hospital, London, UK
l The Horton General Hospital, Banbury, UK
l Jersey General Hospital, Jersey, UK
l King’s College Hospital, London, UK
l Lister Hospital, Stevenage, UK
l Liverpool Women’s Hospital, Liverpool, UK
l Luton and Dunstable University Hospital, Luton, UK
l Macclesfield District General Hospital, Macclesfield, UK
l Walsall Manor Hospital, Walsall, UK
l Medway Maritime Hospital, Gillingham, UK
l Midland Regional Hospital, Mullingar, Republic of Ireland
l Milton Keynes University Hospital, Milton Keynes, UK
l Musgrove Park Hospital, Taunton, UK
l NIHR Clinical Research Network West Midlands, UK
l NIHR Clinical Research Network Yorkshire and Humber, UK
l Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK
l North Devon District Hospital, Barnstaple, UK
l North Middlesex University Hospital, London, UK
l Northumbria Specialist Emergency Care Hospital, Cramlington, UK
l Ormskirk and District General Hospital, Ormskirk, UK
l Peterborough City Hospital, Peterborough, UK
l Pilgrim Hospital, Boston, UK
l Poole Hospital, Poole, UK
l Portiuncula Hospital, Co. Galway, Republic of Ireland
l Princess Elizabeth Hospital, Le Vanquiedor, Guernsey, UK
l Princess of Wales Hospital, Bridgend, UK
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l Queen Elizabeth Hospital, Gateshead, UK
l Queen Elizabeth Hospital, King’s Lynn, UK
l Queen’s Hospital, Burton-on-Trent, UK
l Raigmore Hospital, Inverness, UK
l Rotherham General Hospital, Rotherham, UK
l Royal Alexandra Children’s Hospital, Brighton, UK
l Royal Hampshire County Hospital, Winchester, UK
l The Royal London Hospital, London, UK
l Royal United Hospital, Bath, UK
l Russells Hall Hospital, Dudley, UK
l Salisbury District Hospital, Salisbury, UK
l Scarborough General Hospital, Scarborough, UK
l Scunthorpe General Hospital, Scunthorpe, UK
l Sligo University Hospital, Sligo, Republic of Ireland
l South Tyneside District Hospital, South Shields, UK
l St Helens and Knowsley Teaching Hospitals NHS Trust, Whiston, UK
l St Helier Hospital, Carshalton, UK
l St John’s Hospital, Livingston, UK
l St Mary’s Hospital, Isle of Wight, UK
l St Richard’s Hospital, Chichester, UK
l Stoke Mandeville Hospital, Aylesbury, UK
l Torbay Hospital, Torquay, UK
l University Hospital Crosshouse, Kilmarnock, UK
l University Hospital Lewisham, London, UK
l University Hospital of North Durham, Durham, UK
l Victoria Hospital, Kirkcaldy, UK
l Wansbeck General Hospital, Ashington, UK
l Warwick Hospital, Coventry, UK
l West Cumberland Hospital, Whitehaven, UK
l Wexham Park Hospital, Slough, UK
l Worthing Hospital, Worthing, UK.
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Appendix 3 Case definition of survival
without moderate or severe disability
For the purposes of the blinded end-point review of follow-up data, five outcomes will beconsidered:
1. Survival without moderate or severe disability at 24 months of age CGA. This is the primary outcome.
2. Survival without moderate or severe vision impairment.
3. Survival without moderate or severe hearing impairment.
4. Survival without moderate or severe gross motor impairment.
5. Survival without moderate or severe cognitive/language impairment.
Review conventions
The four components will be defined as follows:
1. Moderate/severe vision impairment – reduced vision uncorrected with aids, blind in one eye with
good vision in the contralateral eye or is blind or can perceive light only.
2. Moderate/severe hearing impairment – hearing loss corrected with aids, some hearing but loss not
corrected by aids or deaf.
3. Moderate/severe gross motor impairment – unable to walk independently or unable to
sit independently.
4. Moderate/severe cognitive impairment – child’s development is between 6 and 12 months behind
corrected age, child’s development > 12 months behind corrected age, child has fewer than five
meaningful words, vocalisations or signs or child is unable to understand words or signs.
These definitions are taken from the protocol apart from the definition of moderate/severe cognitive
impairment. In the protocol it was stated that moderate/severe cognitive impairment would be
assessed using the PARCA-R, a parent-reported measure of non-verbal cognitive and language
development. Total PARCA-R scores of < 44 would be used to identify children with moderate/severe
cognitive impairment. Participants whose data are reviewed will be unlikely to have a fully completed
valid PARCA-R questionnaire.
If the child is classed as having moderate/severe impairment in one of the four domains above, then
they will be classed as having moderate/severe disability in terms of the primary outcome.
If the only data available for the child are scores on the Bayley Scales of Infant and Toddler
Development, third edition (Bayley-III), from an assessment performed between 22 and 28 months of
age (CGA), these should be interpreted as follows:
l Standardised composite score of ≤ 84 (equivalent to a scaled score of ≤ 6) in any domain denotes
moderate to severe impairment.
l If the child was able to complete the Bayley-III, particularly the cognitive and language scales, with
scores in the normal range, it should be assumed that the child has mild/no visual impairment
(even if this is not stated).
If Bayley-III scores are available in addition to clinical information, the scores should be interpreted in
the light of that information, particularly where scores are close to the cut-off points for moderate/
severe impairment listed above. Bayley-III is not the primary outcome measure and the cut-off points
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above are not formally agreed standards. Thus, reviewers should interpret in the light of other
information where scores are close to the cut-off.
Where there is a detailed clinic letter that provides evidence of no concerns regarding developmental
progress (i.e. cognitive, language, motor), it should be assumed that there is also no moderate to severe
hearing impairment, unless otherwise stated.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Appendix 4 British Association of Perinatal
Medicine categories of care
Definitions are reproduced with permission from British Association of Perinatal Medicine.116
Intensive care
General principle
This is care provided for infants who are the most unwell or unstable and have the greatest needs in
relation to staff skills and staff-to-patient ratios.
Definition of intensive care day
l Any day when an infant receives any form of mechanical respiratory support via a tracheal tube.
l Both non-invasive ventilation [e.g. nasal continuous positive airway pressure (CPAP), synchronised
inspiratory positive airway pressure (SIPAP), bilevel positive airway pressure (BIPAP) and Vapotherm
(Vapotherm Inc., Exeter, NH, USA)] and parenteral nutrition (PN).
l Day of surgery [including laser therapy for retinopathy of prematurity (ROP)].
l Day of death.
l Any day receiving any of the following:
¢ presence of an umbilical arterial line
¢ presence of an umbilical venous line
¢ presence of a peripheral arterial line
¢ insulin infusion
¢ presence of a chest drain
¢ exchange transfusion
¢ therapeutic hypothermia
¢ prostaglandin infusion
¢ presence of replogle tube
¢ presence of epidural catheter
¢ presence of silo for gastroschisis
¢ presence of external ventricular drain
¢ dialysis (any type).
High-dependency care
General principle
This is the care that is provided for infants who require highly skilled staff but where the nurse-to-patient
ratio is less than that in intensive care.
Definition of high-dependency care day
A high-dependency care day is any day when an infant does not fulfil the criteria for intensive care
where any of the following apply:
l Any day when an infant receives any form of non-invasive respiratory support (e.g. nasal CPAP,
SIPAP, BIPAP, humidified high-flow nasal cannula).
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l Any day receiving any of the following:
¢ parenteral nutrition
¢ continuous infusion of drugs (except prostaglandin and/or insulin)
¢ presence of a central venous or long line (peripherally inserted central catheter)
¢ presence of a tracheostomy
¢ presence of a urethral or suprapubic catheter.
Special care
General principle
Special care is provided for infants who require additional care delivered by the neonatal service but
do not require either intensive care or high-dependency care.
Definition of special care day
A special care day is any day when an infant does not fulfil the criteria for intensive or
high-dependency care and requires any of the following:
l oxygen by nasal cannula
l feeding by nasogastric, jejunal tube or gastrostomy
l continuous physiological monitoring (excluding apnoea monitors only)
l care of a stoma
l presence of intravenous cannula
l phototherapy
l special observation of physiological variables at least 4-hourly.
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Appendix 5 Data collection forms
Name of form Description
Form 1: trial entry Completed before, during and after randomisation, collecting data on
baseline characteristics and eligibility/exclusion criteria
Form 2: daily feed log Completed daily starting at randomisation. Records data for each day in the
study until the infant reaches full feeds (150ml/kg/day) for 3 consecutive
days, or until their participation in the trial stops for other reasons. Also
records daily use of antibiotics and feed stops for ≥ 4 hours
Form 3: late-onset infection Completed for each episode of microbiologically confirmed or clinically
suspected late-onset invasive infection, from trial entry to discharge home
Form 4: gut signs Completed when the infant received > 5 days of treatment for gut signs
(e.g. feeds withheld), from trial entry to discharge home
Form 5: hospital transfer and discharge Completed when the infant is transferred to another hospital, is discharged
home or if the infant died
Form 6: discontinuation of intervention Completed when a parent or clinician decided to stop the allocated SIFT
feeding regimen permanently
Form 7: serious adverse events Completed for all reportable SAEs as defined in the trial protocol
Form 8: incident reporting Completed in the event of any deviation from the trial protocol, other
trial-specific procedures, good clinical practice or other regulations and
legislation
2-year follow-up questionnaire Sent directly to parents of surviving infants shortly before the infant’s
24-month corrected age. The form collected data on the primary outcome
(survival without moderate or severe disability), individual components
of the primary outcome, the PARCA-R, and health service access and
resource use
Copies of SIFT data collection forms are available at www.npeu.ox.ac.uk/sift/dcfs
(accessed 29 January 2020).
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Appendix 6 Safety reporting definitions
Serious adverse event
Adverse events are defined as serious if they:
l result in death
l are life-threatening
l require inpatient hospitalisation or prolongation of existing hospitalisation
l result in persistent or significant disability/incapacity
l are a congenital anomaly/birth defect.
The term ‘life-threatening’ refers to an event in which the participant was at risk of death at the time
of the event; it does not refer to an event that hypothetically might have caused death if it were
more severe.
The SAEs are to be reported from randomisation to discharge home.
Expected serious adverse events
The following are SAEs that could be reasonably expected to occur in this population of infants during
the course of the trial or form part of the outcome data. They do not require reporting by the SIFT
co-ordinating centre as SAEs:
l death (unless unexpected in this population)
l NEC or focal intestinal perforation
l microbiologically confirmed or clinically suspected late-onset invasive infection
l bronchopulmonary dysplasia (mechanical ventilator support or supplemental oxygen at 36 weeks’
postmenstrual age)
l intracranial abnormality (haemorrhage, parenchymal infarction or white matter damage) on cranial
ultrasound scan or other imaging
l pulmonary haemorrhage
l patent ductus arteriosus requiring treatment (non-steroidal anti-inflammatory drugs or surgery)
l retinopathy of prematurity.
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Appendix 7 Summary of changes to the study
protocol
Date Summary of changes
Version
number
12 December 2012 Version 1 of the protocol33 was submitted to the REC on 20 December 2012 and
approved on 31 January 2013
1
8 July 2013 A protocol amendment was submitted to the REC on 8 July 2013 and approved on
19 August 2013. Changes were as follows:
l The protocol was modified for clarity and consistency both within the document
and with the parent information leaflet and consent form. Minor grammatical
and formatting errors were also corrected
l More significant changes were made to sections 10.2 Statistical Analysis,
10.3 Economic Analysis, 10.4 Economic Data Collection, 12.5 Risk Assessment,
12.6 National Registration Systems and 16.4 Project Management Group (PMG)
2
15 September 2014 l The secondary outcomes section was amended to clarify that the separate
components of the composite primary outcome would also be analysed
separately as secondary outcomes
l Added clarification that SAEs should be reported from randomisation to the
point where the infant is discharged home
l In the list of ‘expected’ SAEs, the definition of bronchopulmonary dysplasia was
amended from ‘at 36 weeks of age corrected for prematurity’ to ‘36 weeks’
postmenstrual age’
l The rationale for increasing the sample size from 2500 to 2800 was added to
section 8.1
l A statement that ‘unidentifiable data from this study may be shared with other
groups carrying out similar work’ was added to section 11.3
l ‘Head of Trials’ was changed to ‘CTU Director’ in section 14.4 describing the
Project Management Group
l ‘Hospital discharge’ was changed to ‘discharged home’ throughout
l The description of the trial groups was changed throughout. ‘Fast’ was changed
to ‘Faster’ and ‘Slow’ to ‘Slower’
l There were additional minor changes to formatting and punctuation
3
24 June 2015 Changed reference to reimbursement in preparation for possible incentives SWAT
(subject to HTA and ethics approval)
4
7 December 2015 Never released: clarified methods of capturing outcome data. Added survival to
discharge home as secondary outcome
5
4 February 2016 Additional clarification of methods of capturing outcome data. Supersedes v5 that
was never submitted to ethics; numbered v5.1 to keep track of alterations
internally
5.1
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Appendix 8 Withdrawals from intervention
by randomisation group
Reason for withdrawal Faster (30ml/kg/day) (N= 1400),a n Slower (18ml/kg/day) (N= 1404),a n
Clinical decision
Total 12 23
Consent remains 12 21
Consent completely withdrawn 0 2
Parental wish
Total 17 14
Consent remains 11 11
Consent completely withdrawn 6 3
Overall total 29 37
a Includes all infants randomised.
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Appendix 9 Group allocation per
recruiting site
Centre
Faster increment group
(N= 1394), n (%)
Slower increment group
(N= 1399), n (%)
Jessop Wing, Sheffield 38 (2.7) 39 (2.8)
Royal Infirmary of Edinburgh 63 (4.5) 61 (4.4)
Princess Royal Maternity Hospital, Glasgow 37 (2.7) 46 (3.3)
Southern General Hospital, Glasgow 34 (2.4) 32 (2.3)
Wishaw General Hospital 27 (1.9) 28 (2.0)
Royal Maternity Hospital, Belfast 15 (1.1) 13 (0.9)
James Cook University Hospital, Middlesbrough 48 (3.4) 54 (3.9)
Nottingham City Hospital 33 (2.4) 33 (2.4)
Queen’s Medical Centre University Hospital 23 (1.6) 23 (1.6)
Birmingham Heartlands Hospital 33 (2.4) 34 (2.4)
Birmingham Women’s Hospital 70 (5.0) 73 (5.2)
Birmingham City Hospital 28 (2.0) 29 (2.1)
Royal Berkshire Hospital, Reading 8 (0.6) 8 (0.6)
Derbyshire Children’s Hospital 13 (0.9) 10 (0.7)
Sunderland Royal Hospital 30 (2.2) 30 (2.1)
Altnagelvin Area Hospital, Londonderry 7 (0.5) 5 (0.4)
Worcestershire Royal Hospital 8 (0.6) 7 (0.5)
Royal Shrewsbury Hospital 25 (1.8) 25 (1.8)
King’s Mill Hospital, Sutton-in-Ashfield 1 (0.1) 0
New Cross Hospital, Wolverhampton 10 (0.7) 10 (0.7)
University Hospital Coventry 45 (3.2) 44 (3.1)
Royal Victoria Infirmary, Newcastle 59 (4.2) 57 (4.1)
Arrowe Park Hospital, Wirral 22 (1.6) 23 (1.6)
University Hospital of North Tees 40 (2.9) 35 (2.5)
John Radcliffe Hospital, Oxford 45 (3.2) 41 (2.9)
Lincoln County Hospital 3 (0.2) 6 (0.4)
Hull Royal Infirmary 23 (1.6) 23 (1.6)
Bradford Royal Infirmary 62 (4.4) 61 (4.4)
Calderdale Royal Hospital 20 (1.4) 17 (1.2)
Countess of Chester Hospital 3 (0.2) 3 (0.2)
Derriford Hospital, Plymouth 1 (0.1) 2 (0.1)
Gloucestershire Royal Hospital 7 (0.5) 6 (0.4)
Kettering General Hospital 4 (0.3) 4 (0.3)
Leeds General Infirmary 58 (4.2) 58 (4.1)
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Centre
Faster increment group
(N= 1394), n (%)
Slower increment group
(N= 1399), n (%)
Leicester Royal Infirmary 54 (3.9) 55 (3.9)
Leighton Hospital, Crewe 1 (0.1) 4 (0.3)
Northampton General Hospital 3 (0.2) 7 (0.5)
Pinderfields General Hospital, Wakefield 4 (0.3) 4 (0.3)
Princess Anne Hospital, Southampton 25 (1.8) 26 (1.9)
Queen Alexandra Hospital, Portsmouth 82 (5.9) 80 (5.7)
Royal Cornwall Hospital, Truro 7 (0.5) 10 (0.7)
Royal Devon and Exeter Hospital 25 (1.8) 26 (1.9)
Singleton Hospital, Swansea 29 (2.1) 33 (2.4)
Southmead Hospital, Bristol 24 (1.7) 23 (1.6)
St George’s Hospital, London 25 (1.8) 24 (1.7)
St James’s University Hospital, Leeds 22 (1.6) 18 (1.3)
St Michael’s Hospital, Bristol 15 (1.1) 15 (1.1)
St Peters Hospital, Chertsey 32 (2.3) 35 (2.5)
Warrington Hospital 4 (0.3) 3 (0.2)
William Harvey Hospital, Ashford 24 (1.7) 23 (1.6)
York Hospital 4 (0.3) 5 (0.4)
University Hospital of North Staffordshire 18 (1.3) 14 (1.0)
Croydon University Hospital 13 (0.9) 11 (0.8)
National Maternity Hospital, Dublin 28 (2.0) 32 (2.3)
Queen’s Hospital, Romford 12 (0.9) 11 (0.8)
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Appendix 10 Strategies to enhance follow-up
return rates
A number of strategies were adopted to enhance the return of questionnaires. These included:
l Contacting parents via telephone or text message earlier in the follow-up process – making a
telephone call to parents to remind them of their child’s participation in SIFT and check their
contact details, 4 days before their follow-up questionnaire was due to be posted out.
l Contacting parents via telephone as well as by post if a second reminder was required (rather than
waiting until a third reminder to begin telephoning).
l Where parents had supplied a mobile telephone number and/or e-mail address, sending e-mail/SMS
reminders in addition to postal letters.
l Requesting that recruiting sites remind parents of the follow-up questionnaire if and when they
attended a clinical appointment at 24 months of age.
l Supplying recruiting and continuing care sites with a poster to display in clinic waiting rooms
reminding parents of the follow-up.
l Offering parents the option of completing the questionnaire online via a direct link, using a new
product called OpenClinica Participate 3.3 to 3.13 (OpenClinica LLC, Waltham, MA, USA). SIFT was
part of the piloting for this new software.
l Having the follow-up promoted on a quarterly basis via social media platforms through the trial’s
service-user advocate partner, the charity Bliss.
l An embedded SWAT offering incentives to participants to complete the questionnaire (see Chapter 6).
This SWAT investigated the effects of giving an incentive (£15/€15 high-street shop voucher) before
completion compared with promising an incentive on receipt of a completed questionnaire.
Figure 9 displays the changes in follow-up rate throughout the process.
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FIGURE 9 Interventions and changes in SIFT follow-up rate.
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